Migrators and uses thereof

Migrations containing antigens and immune co-stimulatory molecules were prepared by low-osmotic pressure treatment and cytoskeleton disruption, solving the problem of preparing non-genetically modified cell migrations and achieving highly efficient immune response induction and tumor treatment effects.

CN119020288APending Publication Date: 2024-11-26BEIJING MIGRASOME THERAPEUTICS LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410658555.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-24
Filing Date
2024-05-24
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing technologies struggle to effectively utilize the migratory bodies produced from unmodified cells, especially in maintaining their antigenicity and immunomodulatory functions during preparation, and lack efficient preparation methods and convenient in vivo biodistribution.

Method used

By treating with low osmotic pressure, disrupting the cytoskeleton, and overexpressing Tetraspanin family proteins, combined with separation and purification steps, a migratory organism containing antigens and immune co-stimulatory molecules was prepared. This organism is suitable for in vivo biodistribution and exhibits high yield and low toxicity.

Benefits of technology

It has achieved efficient preparation of migrations with antigenic and immunomodulatory functions, which can induce and regulate immune responses and are suitable for the prevention and treatment of diseases such as tumors. It has a simple preparation method and good in vivo distribution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004861351320000011
    Figure HDA0004861351320000011
  • Figure HDA0004861351320000012
    Figure HDA0004861351320000012
  • Figure HDA0004861351320000021
    Figure HDA0004861351320000021
Patent Text Reader

Abstract

The invention relates to a migration body and application thereof. The migration body can induce and / or regulate immune response.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biomedicine, and specifically to a migration body and its use. Background Art

[0002] Migrasome is a cell organelle. During cell migration, the cell body continuously transports intracellular substances to the migrasome. Subsequently, the contractile filaments break and the migrasome is released. It can be transported to the distal tissue at the local site or through body fluids such as blood, and then taken up by the extracellular space or surrounding cells. This indicates that the migrasome may be involved in the transmission of intracellular substances and signals between cells, thereby mediating intercellular communication (Liang Ma et.al., Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration, Cell Res (2015) 25: 24-38).

[0003] Engineered migrasomes are vesicles with certain similarities to migrasome structures that are produced when cells undergo relative displacement induced by external stimulation, including physical and / or chemical stimulation. Studies have shown that migrasomes play an important role in signal transmission in active cell migration processes such as embryonic development, immune response, tumors, angiogenesis, and tissue regeneration, and it is of great significance to realize therapeutic uses and other applications based on migrasomes. Summary of the invention

[0004] The present application provides a migrator and its use, wherein the migrator may have one or more of the following characteristics: having an antigen, having a molecule related to antigen presentation, having a wide antigen coverage, not requiring sequencing and predicting antigen epitopes, being able to induce and / or regulate immune responses, having low toxicity, having a suitable in vivo biodistribution, having a simple preparation method, having a short production cycle, and having a high yield. The migrator described in the present application can be used to prevent and / or treat diseases.

[0005] In one aspect, the present invention provides a migrator, wherein the migrator contains an antigen and is produced from cells that are not directly genetically modified, wherein the migrator is produced from a tumor cell.

[0006] According to a specific embodiment of the present invention, the antigen comprises a tumor antigen.

[0007] According to a specific embodiment of the present invention, the migrating body contains MHC molecules and / or immune co-stimulatory molecules.

[0008] According to a specific embodiment of the present invention, the migrating body contains a major histocompatibility complex (MHC)-peptide complex or a variant thereof.

[0009] According to a specific embodiment of the present invention, the tumor cells are selected from human tumor cell lines or human primary tumor cells.

[0010] According to a specific embodiment of the invention, tumor cells are isolated from a sample from a cancer patient.

[0011] According to a specific embodiment of the present invention, the sample is a biopsy sample or a surgically removed tumor tissue sample.

[0012] According to a specific embodiment of the invention, the cancer is a solid tumor or a hematological tumor.

[0013] According to a specific embodiment of the present invention, the cancer is selected from breast cancer, fibrosarcoma, colorectal cancer, lung cancer, gastric cancer, liver cancer, kidney cancer, ovarian cancer, pancreatic cancer, bladder cancer, prostate cancer, skin cancer, head and neck cancer, brain cancer, leukemia, lymphoma, myeloma.

[0014] According to a specific embodiment of the present invention, the patient is a patient who has received a previous treatment or a patient who has not received a previous treatment.

[0015] According to a specific embodiment of the invention, the previous treatment is selected from surgery, chemotherapy, immunotherapy and radiotherapy.

[0016] According to a specific embodiment of the present invention, the tumor cells are selected from human primary skin squamous cell carcinoma cells, mouse MC38 cells, mouse B16F10 melanoma tumor cells, mouse fibrosarcoma MCA-205 cells and mouse breast cancer 4T1 cells.

[0017] According to a specific embodiment of the present invention, the migrating body includes a migrating body produced in vitro or ex vivo.

[0018] According to a specific embodiment of the present invention, the migrating body is prepared by a method comprising the following steps:

[0019] (a) treating cells with one or more of the following to induce the cells to produce migrasomes:

[0020] (1) Hypoosmotic pressure treatment;

[0021] (2) destroying the cytoskeleton of the cell;

[0022] (3) inhibiting the cell volume regulation function of the cell; and

[0023] (4) causing the cell to overexpress one or more proteins selected from members of the Tetraspanin family; and

[0024] (b) isolating and / or purifying the migrating body.

[0025] According to a specific embodiment of the present invention, the migrasome is prepared by subjecting the cells to a low osmotic pressure treatment and destroying the cytoskeleton of the cells.

[0026] According to a specific embodiment of the present invention, the low osmotic pressure treatment comprises placing the cells in a buffer solution, and reducing the osmotic pressure of the buffer solution to 30.5-274.5 mOsmol, such as 30.5-150 mOsmol.

[0027] According to a specific embodiment of the present invention, disrupting the cytoskeleton of the cell comprises contacting the cell with a cytoskeleton disrupting agent selected from the group consisting of Latrunculin A, Latrunculin B, cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D and cytochalasin E.

[0028] According to a specific embodiment of the present invention, the migrator contains molecules selected from the following: molecules involved in antigen presentation (such as MHC molecules and / or immune co-stimulatory molecules), chemokines and / or their receptors, adhesion factors, sodium / potassium ATPases and integrins (such as ITGAV, ITGA5, ITGB1); preferably, the migrator contains MHC molecules.

[0029] According to a specific embodiment of the present invention, the ratio of cholesterol concentration to total protein concentration of the migrator is higher than that of the cell from which it is derived, and / or

[0030] The ratio of sphingomyelin concentration to total protein concentration of the migrator is higher than that of the cell from which it originates, and / or

[0031] The cholesterol:phosphatidylglycerol ratio of the migrasome is higher than that of the cells from which it originates.

[0032] According to a specific embodiment of the invention, the migasome is capable of inducing and / or modulating an immune response.

[0033] According to a specific embodiment of the present invention, the immune response is selected from inducing activation of immune cells, production and / or secretion of cytokines, antibodies and / or other active molecules, increasing the killing function of immune cells, inducing immune memory, and increasing immune cell infiltration of tumors.

[0034] According to a specific embodiment of the present invention, the cytokine comprises interferon (IFN).

[0035] According to a specific embodiment of the present invention, the interferon comprises IFNγ.

[0036] According to a specific embodiment of the present invention, the immune response includes inducing immunological memory.

[0037] In another aspect, the present invention provides a vaccine composition comprising the migrator of the present invention.

[0038] According to a specific embodiment of the present invention, the vaccine composition comprises an immunological adjuvant.

[0039] According to a specific embodiment of the present invention, the adjuvant is polyinosinic acid cytosine nucleotide (Poly I:C).

[0040] In another aspect, the present invention provides a pharmaceutical composition comprising the migrator or vaccine composition of the present invention.

[0041] According to a specific embodiment of the invention, the pharmaceutical composition comprises an additional therapeutic agent.

[0042] According to a specific embodiment of the invention, the additional therapeutic agent is an immunomodulatory agent.

[0043] According to a specific embodiment of the present invention, the immunomodulator is selected from antibodies or antigen binding proteins, binding fragments, receptors, ligands and / or compounds or any combination thereof.

[0044] In another aspect, the present invention provides use of the migrator or the vaccine composition in preparing a medicament for preventing and / or treating a disease in a subject.

[0045] According to a specific embodiment of the present invention, the disease is a tumor.

[0046] According to a specific embodiment of the present invention, the tumor is a solid tumor or a hematological tumor.

[0047] According to a specific embodiment of the invention, the method comprises the use of an additional therapeutic agent.

[0048] According to a specific embodiment of the invention, the additional therapeutic agent is an immunomodulatory agent.

[0049] According to a specific embodiment of the present invention, the immunomodulator is selected from antibodies or antigen binding proteins, binding fragments, receptors, ligands and / or compounds or any combination thereof.

[0050] According to a specific embodiment of the invention, the migrasomes are autologous to said subject, for example generated from tumor cells isolated from a sample from said subject.

[0051] In another aspect, the present invention provides a method of treating cancer in a subject, the method comprising:

[0052] (a) obtaining a sample comprising tumor cells from the subject;

[0053] (b) isolating the tumor cells from the sample and culturing the tumor cells under conditions suitable for tumor cell growth;

[0054] (c) generating migrasomes from the tumor cells;

[0055] (d) administering the migrating body to the subject.

[0056] According to a specific embodiment of the present invention, the sample is a biopsy sample or a tumor tissue sample removed by surgery.

[0057] According to a specific embodiment of the present invention, the subject has received previous treatment or has not received previous treatment.

[0058] According to a specific embodiment of the present invention, the previous treatment is selected from surgery, chemotherapy, immunotherapy and radiotherapy.

[0059] In another aspect, the present invention provides a method for preventing cancer in a subject, the method comprising:

[0060] (a) obtaining tumor cells;

[0061] (b) generating migrasomes from the tumor cells;

[0062] (c) administering the migrating body to the subject.

[0063] According to a specific embodiment of the present invention, the tumor cells are from a human tumor cell line or a human primary tumor cell.

[0064] According to a specific embodiment of the invention, the cancer is a solid tumor or a hematological tumor.

[0065] According to a specific embodiment of the present invention, the cancer is selected from breast cancer, fibrosarcoma, colorectal cancer, lung cancer, gastric cancer, liver cancer, kidney cancer, ovarian cancer, pancreatic cancer, bladder cancer, prostate cancer, skin cancer, head and neck cancer, brain cancer, leukemia, lymphoma, myeloma.

[0066] According to a specific embodiment of the present invention, generating migrasomes from the tumor cells comprises:

[0067] (a) subjecting the tumor cells to one or more of the following treatments to induce the tumor cells to produce migratory bodies:

[0068] (1) Hypoosmotic pressure treatment;

[0069] (2) destroying the cytoskeleton of the cell;

[0070] (3) inhibiting the cell volume regulation function of the cell; and

[0071] (4) causing the cell to overexpress one or more proteins selected from members of the Tetraspanin family; and

[0072] (b) isolating and / or purifying the migrating body.

[0073] According to a specific embodiment of the present invention, the migrasome is prepared by subjecting the tumor cells to a low osmotic pressure treatment and destroying the cytoskeleton of the cells.

[0074] According to a specific embodiment of the present invention, the low osmotic pressure treatment comprises placing the cells in a buffer solution, and reducing the osmotic pressure of the buffer solution to 30.5-274.5 mOsmol, such as 30.5-150 mOsmol.

[0075] According to a specific embodiment of the present invention, disrupting the cytoskeleton of the cell comprises contacting the cell with a cytoskeleton disrupting agent selected from the group consisting of Latrunculin A, Latrunculin B, cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D and cytochalasin E.

[0076] According to a specific embodiment of the invention, the method further comprises administering a second agent.

[0077] According to a specific embodiment of the present invention, the second agent is selected from the group consisting of an immunomodulator, an antibody, a chemotherapeutic agent and a small molecule drug.

[0078] In one aspect, the present application provides a migrator, wherein the migrator contains an antigen and is produced from cells that have not been directly genetically modified.

[0079] In another aspect, the present application provides a migrating body, wherein the migrating body contains an antigen and is produced from a sample of a subject.

[0080] According to any aspect of the present invention, the antigen is present on the surface and / or inside the migrating body.

[0081] According to any aspect of the present invention, the antigen comprises an endogenous or exogenous antigen.

[0082] According to any aspect of the present invention, the antigen comprises an endogenous antigen.

[0083] According to any aspect of the present invention, the antigen comprises a tumor antigen.

[0084] According to any aspect of the present invention, the antigen comprises a tumor cell antigen.

[0085] According to any aspect of the present invention, the antigen comprises a tumor neoantigen.

[0086] In another aspect, the present application provides a migsome, wherein the migsome contains a molecule involved in antigen presentation, and the migsome is produced from cells that have not been directly genetically modified.

[0087] In another aspect, the present application provides a migrating body, wherein the migrating body contains a molecule involved in antigen presentation, and the migrating body is generated from a subject sample. In certain embodiments, the molecule involved in antigen presentation is present on the surface and / or inside the migrating body.

[0088] According to any aspect of the present invention, the migrating body contains MHC molecules and / or immune co-stimulatory molecules.

[0089] According to any aspect of the present invention, the migrating body contains a major histocompatibility complex (MHC)-peptide complex or a variant thereof.

[0090] On the other hand, the present application provides a migrator that can induce and / or regulate an immune response, and the migrator is produced from cells that have not been directly genetically modified.

[0091] In another aspect, the present application provides a migrator-like organism that is capable of inducing and / or regulating an immune response and is produced from a sample of a subject.

[0092] According to any aspect of the present invention, the immune response comprises activation of immune cells.

[0093] According to any aspect of the present invention, the immune cells include lymphocytes.

[0094] According to any aspect of the present invention, the immune cells include T cells, B cells, NK cells and / or antigen presenting cells.

[0095] According to any aspect of the present invention, the immune cells include antigen presenting cells.

[0096] According to any aspect of the present invention, the immune response includes inducing activation of immune cells.

[0097] According to any aspect of the present invention, the immune cell activation comprises inducing the expression and / or upregulation of immune cell activation molecules.

[0098] According to any aspect of the present invention, the activation molecules include but are not limited to CD80, CD86, MHC, CD25, and CD69.

[0099] According to any aspect of the present invention, the immune response includes the production and / or secretion of cytokines, antibodies and / or other active molecules.

[0100] According to any aspect of the present invention, the cytokine comprises interferon (IFN).

[0101] According to any aspect of the present invention, the interferon comprises IFNγ.

[0102] According to any aspect of the present invention, the immune response includes increasing the killing function of immune cells.

[0103] According to any aspect of the present invention, the killing function comprises increasing the production and / or release of substances that mediate cell killing.

[0104] According to any aspect of the present invention, the substance that mediates cell killing includes but is not limited to perforin and / or granzyme.

[0105] According to any aspect of the present invention, the immune response comprises inducing immune memory.

[0106] According to any aspect of the present invention, the immune response comprises increasing immune cell infiltration of the tumor.

[0107] According to any aspect of the present invention, the migrasomes are generated from tissues or ex vivo cells.

[0108] According to any aspect of the present invention, the migrasome is produced from living cells.

[0109] According to any aspect of the present invention, the migrasome is produced from cells derived from an organism.

[0110] According to any aspect of the present invention, the organism comprises a human, a monkey, a mouse, a rat, a dog, a rabbit, a chicken and / or an insect.

[0111] According to any aspect of the present invention, the cells producing migrasomes include but are not limited to tissue cells.

[0112] According to any aspect of the present invention, the cells producing migrasomes include but are not limited to tumor cells.

[0113] According to any aspect of the present invention, the cells producing migrasomes include but are not limited to cells cultured in vitro.

[0114] According to any aspect of the present invention, the cells producing migrasomes include cell lines, primary cells, cells with limited passage and / or organoids.

[0115] According to any aspect of the present invention, the cells producing migrasomes include but are not limited to cells cultured in suspension or adherent culture.

[0116] According to any aspect of the present invention, the cells producing migrasomes include primary or limited-passage tumor cells, tumor stromal cells, and / or tumor organoids derived from an organism.

[0117] According to any aspect of the present invention, the cells producing migrasomes include but are not limited to mouse tumor cell lines or primary tumor cells.

[0118] According to any aspect of the present invention, the cells producing migrasomes include but are not limited to mouse fibrosarcoma MCA-205 cells and / or mouse breast cancer 4T1 cells.

[0119] According to any aspect of the present invention, the cells producing migrasomes include cells derived from humans, and the cells derived from humans include human tumor cell lines or human primary tumor cells.

[0120] According to any aspect of the present invention, the cells producing migrasomes are cells from tissues that have not been cultured in vitro.

[0121] According to any aspect of the present invention, the migrating body includes a migrating body produced in vitro or ex vivo.

[0122] According to any aspect of the present invention, the migrating body is an engineered migrating body.

[0123] According to any aspect of the present invention, the contents of the migrasomes are at least partially reduced or absent compared to natural migrasomes produced by corresponding cells.

[0124] According to any aspect of the present invention, the at least partially reduced contents include but are not limited to intraluminal vesicles.

[0125] According to any aspect of the present invention, the migrator is prepared by a method for preparing an engineered migrator, the preparation method comprising causing cells to undergo relative displacement and then producing migrator derived from the cells.

[0126] According to any aspect of the present invention, the preparation method comprises isolating migrasomes produced by the cells.

[0127] According to any aspect of the present invention, the preparation method comprises subjecting the cells to a low osmotic pressure treatment.

[0128] According to any aspect of the present invention, the hypotonic pressure treatment comprises placing the cells in a hypotonic buffer solution.

[0129] According to any aspect of the present invention, the hypotonic pressure treatment comprises placing the cells in a buffer solution and reducing the osmotic pressure of the buffer solution to a hypotonic buffer solution.

[0130] According to any aspect of the present invention, the reduction comprises a linear reduction and / or a step-wise reduction.

[0131] According to any aspect of the present invention, the osmotic pressure of the hypotonic buffer solution is lower than about 305 mOsmol / L.

[0132] According to any aspect of the present invention, the osmotic pressure of the hypotonic buffer solution is about 10 mOsmol / L to about 274.5 mOsmol / L.

[0133] According to any aspect of the present invention, it comprises disrupting the cytoskeleton of said cell.

[0134] According to any aspect of the present invention, disrupting the cytoskeleton of the cell comprises contacting the cell with a cytoskeleton disrupting agent.

[0135] According to any aspect of the present invention, the agent that destroys the cytoskeleton comprises a microfilament and / or microtubule depolymerizing agent.

[0136] According to any aspect of the present invention, the agent that disrupts the cytoskeleton comprises Latrunculin A, Latrunculin B, cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D and / or cytochalasin E.

[0137] According to any aspect of the present invention, the preparation method comprises inhibiting the cell volume regulation function of the cell.

[0138] According to any aspect of the present invention, inhibiting the cell volume regulation function of the cell comprises decreasing the amount and / or function of volume regulatory protein in the cell.

[0139] According to any aspect of the present invention, the volume regulating protein comprises a volume regulating ion channel and / or a transporter.

[0140] According to any aspect of the present invention, the volume regulating ion channel comprises a volume regulating anion channel VRAC and / or a volume regulating cation channel VRCC.

[0141] According to any aspect of the present invention, the volume-regulated anion channel VRAC comprises SWELL1 or a functionally active fragment thereof.

[0142] According to any aspect of the present invention, the volume-regulated cation channel VRCC comprises TRPV4, TRPM3 and / or functionally active fragments thereof.

[0143] According to any aspect of the present invention, wherein the transporter comprises a co-transporter.

[0144] According to any aspect of the present invention, the co-transporter comprises KCC1, KCC3 and / or KCC4.

[0145] According to any aspect of the present invention, wherein inhibiting the cell volume regulation function of the cell comprises placing the cell in a buffer solution with weakened volume regulation ability.

[0146] According to any aspect of the present invention, the buffer solution contains increased cations.

[0147] According to any aspect of the present invention, the cation comprises K + , Na + , Cs + , Li + , Ca 2+ ,Mg 2+ , Ba 2+ , Mn 2 + , Fe 2+ , Ni 2+ , Zn 2+ , Al 3+ , Fe 3+ ,CH3NH3 + , C2H5NH3 + , (CH3)2NH2 + , (C2H5)2NH2 + , (C2H5)3N + , ammonium ions and / or choline ions

[0148] According to any aspect of the present invention, the buffer solution contains increased anions.

[0149] According to any aspect of the present invention, wherein the anion comprises Br - , Cl - , I - , F - , OH - , HCO3 - , H2PO4 - , NO2 - , NO3 - , CN - , HPO4 2- ,CO3 2- , SO4 2- and / or PO4 3- .

[0150] According to any aspect of the present invention, the preparation method comprises releasing the cells from their adhered surfaces.

[0151] According to any aspect of the present invention, the method comprises causing a relative displacement between the cell membrane of the cell and its adhesion surface.

[0152] According to any aspect of the present invention, it further comprises increasing the amount and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell.

[0153] According to any aspect of the present invention, it comprises causing the cell to overexpress the tetraspanin protein, its functional fragment and / or functional variant.

[0154] According to any aspect of the present invention, the tetraspanin protein is selected from the group consisting of: Tspan1, Tspan2, Tspan3, Tspan4, Tspan5, Tspan6, Tspan7, Tspan8, Tspan9, Tspan10, Tspan11, Tspan12, Tspan13, Tspan14, Tspan15, Tspan16, Tspan17, Tspan18, Tspan19, Tsp an20 (UPK1B), Tspan21 (UPK1A), Tspan22 (PRPH2), Tspan23 (ROM1), Tspan24 (CD151), Tspan25 (CD53), Tspan26 (CD37), Tspan27 (CD82), Tspan28 (CD81), Tspan29 (CD9), Tspan30 (CD63), Tspan31, Tspan32 and Tspan33.

[0155] According to any aspect of the present invention, the preparation method comprises reducing the size of the migration body.

[0156] According to any aspect of the present invention, reducing the size of the migration body comprises using a filter, squeezing with a squeezer and / or treating the migration body with an ultrasonicator.

[0157] According to any aspect of the present invention, the pore size of the filter or squeezer is about 30 nm to about 10000 nm.

[0158] According to any aspect of the present invention, the ratio of cholesterol concentration to total protein concentration of the migrator is higher than that of the cell from which it is derived.

[0159] According to any aspect of the present invention, the ratio of cholesterol concentration to total protein concentration of the migrator is at least 50% higher than that of the cell from which it is derived.

[0160] According to any aspect of the present invention, the ratio of sphingomyelin concentration to total protein concentration of the migrator is higher than that of the cell from which it is derived.

[0161] According to any aspect of the present invention, the ratio of sphingomyelin concentration to total protein concentration of the migrator is at least 50% higher than that of the cell from which it is derived.

[0162] According to any aspect of the present invention, the cholesterol:phosphatidylglycerol ratio of the migrator is higher than that of the cell from which it is derived.

[0163] According to any aspect of the present invention, the migrator has a chemokine and / or a receptor thereof.

[0164] According to any aspect of the present invention, the migrating body has an adhesion factor.

[0165] According to any aspect of the present invention, the size of the migrator is about 50 nm to about 8000 nm.

[0166] According to any aspect of the present invention, the migrating body may comprise contractile filaments of the cell.

[0167] According to any aspect of the present invention, the membrane of the migrating body is enriched with sodium / potassium ATPase, its functional variant and / or its functional fragment.

[0168] According to any aspect of the present invention, the membrane of the migrating body is enriched with integrins, functional variants thereof and / or functional fragments thereof.

[0169] According to any aspect of the present invention, the integrin includes but is not limited to ITGAV, ITGA5 and / or ITGB1.

[0170] According to any aspect of the present invention, the membrane of the migrating body is enriched with tetraspanin protein, its functional variant and / or its functional fragment.

[0171] According to any aspect of the present invention, the tetraspanin protein includes but is not limited to TSPAN4, TSPAN7 and TSPAN9.

[0172] According to any aspect of the present invention, cholesterol is enriched on the membrane of the migrating body.

[0173] According to any aspect of the present invention, the migrating body is enriched with membrane microdomains.

[0174] On the other hand, the present application provides a method for producing migratory bodies, comprising causing cells to undergo relative displacement and then producing migratory bodies derived from the cells.

[0175] According to any aspect of the present invention, it further comprises isolating the migrasome produced by the cells.

[0176] According to any aspect of the present invention, it comprises subjecting the cells to a low osmotic pressure treatment.

[0177] According to any aspect of the present invention, the hypotonic pressure treatment comprises placing the cells in a hypotonic buffer solution.

[0178] According to any aspect of the present invention, the hypotonic pressure treatment comprises placing the cells in a buffer solution and reducing the osmotic pressure of the buffer solution to a hypotonic buffer solution.

[0179] According to any aspect of the present invention, the reduction comprises a linear reduction and / or a step-wise reduction.

[0180] According to any aspect of the present invention, the osmotic pressure of the hypotonic buffer solution is lower than about 305 mOsmol / L.

[0181] According to any aspect of the present invention, the osmotic pressure of the hypotonic buffer solution is about 10 mOsmol / L to about 274.5 mOsmol / L.

[0182] According to any aspect of the present invention, it comprises disrupting the cytoskeleton of said cell.

[0183] According to any aspect of the present invention, disrupting the cytoskeleton of the cell comprises contacting the cell with a cytoskeleton disrupting agent.

[0184] According to any aspect of the present invention, the agent that destroys the cytoskeleton comprises a microfilament and / or microtubule depolymerizing agent.

[0185] According to any aspect of the present invention, the agent that disrupts the cytoskeleton comprises Latrunculin A, Latrunculin B, cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D and / or cytochalasin E.

[0186] According to any aspect of the present invention, it comprises inhibiting the cell volume regulation function of said cells.

[0187] According to any aspect of the present invention, inhibiting the cell volume regulation function of the cell comprises decreasing the amount and / or function of volume regulatory protein in the cell.

[0188] According to any aspect of the present invention, the volume regulating protein comprises a volume regulating ion channel and / or a transporter.

[0189] According to any aspect of the present invention, the volume regulating ion channel comprises a volume regulating anion channel VRAC and / or a volume regulating cation channel VRCC.

[0190] According to any aspect of the present invention, the volume-regulated anion channel VRAC comprises SWELL1 or a functionally active fragment thereof.

[0191] According to any aspect of the present invention, the volume-regulating cation channel VRCC comprises TRPV4, TRPM3 and / or functionally active fragments thereof.

[0192] According to any aspect of the present invention, wherein the transporter comprises a co-transporter.

[0193] According to any aspect of the present invention, the co-transporter comprises KCC1, KCC3 and / or KCC4.

[0194] According to any aspect of the present invention, wherein inhibiting the cell volume regulation function of the cell comprises placing the cell in a buffer solution with weakened volume regulation ability.

[0195] According to any aspect of the present invention, the buffer solution contains increased cations.

[0196] According to any aspect of the present invention, the cation comprises K + , Na + , Cs + , Li + , Ca 2+ ,Mg 2+ , Ba 2+ , Mn 2 + , Fe 2+ , Ni 2+ , Zn 2+ , Al 3+ , Fe 3+ ,CH3NH3 + , C2H5NH3 + , (CH3)2NH2 + , (C2H5)2NH2 + , (C2H5)3N + , ammonium ions and / or choline ions.

[0197] According to any aspect of the present invention, the buffer solution contains increased anions.

[0198] According to any aspect of the present invention, wherein the anion comprises Br - , Cl - , I - , F - , OH - , HCO3 - , H2PO4 - , NO2 - , NO3 - , CN - , HPO4 2-,CO3 2- , SO4 2- and / or PO4 3- .

[0199] According to any aspect of the present invention, the method comprises detaching the cells from their adhesion surface.

[0200] According to any aspect of the present invention, the method comprises causing a relative displacement between the cell membrane of the cell and its adhesion surface.

[0201] According to any aspect of the present invention, it further comprises increasing the amount and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell.

[0202] According to any aspect of the present invention, it comprises causing the cell to overexpress the tetraspanin protein, its functional fragment and / or functional variant.

[0203] According to any aspect of the present invention, the tetraspanin protein is selected from the group consisting of: Tspan1, Tspan2, Tspan3, Tspan4, Tspan5, Tspan6, Tspan7, Tspan8, Tspan9, Tspan10, Tspan11, Tspan12, Tspan13, Tspan14, Tspan15, Tspan16, Tspan17, Tspan18, Tspan19, Tsp an20 (UPK1B), Tspan21 (UPK1A), Tspan22 (PRPH2), Tspan23 (ROM1), Tspan24 (CD151), Tspan25 (CD53), Tspan26 (CD37), Tspan27 (CD82), Tspan28 (CD81), Tspan29 (CD9), Tspan30 (CD63), Tspan31, Tspan32 and Tspan33.

[0204] According to any aspect of the present invention, the method further comprises reducing the size of the migration body.

[0205] According to any aspect of the present invention, reducing the size of the migration body comprises using a filter, squeezing with a squeezer and / or treating the migration body with an ultrasonicator.

[0206] According to any aspect of the present invention, the pore size of the filter or squeezer is about 30 nm to about 10000 nm.

[0207] According to any aspect of the invention, it is an in vitro or ex vivo method.

[0208] According to any aspect of the present invention, the cell is a living cell.

[0209] According to any aspect of the present invention, the cell is a cell derived from an organism.

[0210] According to any aspect of the present invention, the organism comprises a human, a monkey, a mouse, a rat, a dog, a rabbit, a chicken and / or an insect.

[0211] According to any aspect of the present invention, the cells are tissue cells.

[0212] According to any aspect of the present invention, the cell is a tumor cell.

[0213] According to any aspect of the present invention, the cells are cells cultured in vitro.

[0214] According to any aspect of the present invention, the cells include cell lines, primary cells and / or cells of limited passage and / or organoids.

[0215] According to any aspect of the present invention, the cells are cells cultured in suspension or adherent culture.

[0216] According to any aspect of the present invention, the cells include primary or limited-passage tumor cells, tumor stromal cells, and / or tumor organoids derived from patients.

[0217] According to any aspect of the present invention, the cells include but are not limited to mouse tumor cell lines or primary tumor cells.

[0218] According to any aspect of the present invention, the cells include but are not limited to mouse fibrosarcoma MCA-205 cells and / or mouse breast cancer 4T1 cells.

[0219] According to any aspect of the present invention, the patient includes humans, and the cells include human tumor cell lines or primary tumor cells derived from tumor tissues.

[0220] According to any aspect of the present invention, the cells are cells derived from tissues that have not been cultured in vitro.

[0221] According to any aspect of the present invention, the method comprises preparing the cells or tissues into a single cell suspension.

[0222] In another aspect, the present application provides a cell having the ability to produce the migratoria described in the present application.

[0223] According to any aspect of the present invention, the cells produce the migrasomes after being treated by the method described in the present application.

[0224] According to any aspect of the present invention, the cells include a single cell suspension thereof.

[0225] In another aspect, the present application provides a vaccine composition, comprising the migrator described in the present application.

[0226] According to any aspect of the present invention, the vaccine composition comprises other immunologically active ingredients.

[0227] According to any aspect of the present invention, the vaccine composition includes but is not limited to an immune adjuvant.

[0228] According to any aspect of the present invention, the vaccine composition includes but is not limited to polyinosinic acid-cytosine nucleotides (Poly I:C).

[0229] According to any aspect of the present invention, the vaccine composition comprises a pharmaceutically acceptable carrier.

[0230] In another aspect, the present application provides a pharmaceutical composition comprising the migrator described in the present application and / or the vaccine composition described in the present application.

[0231] According to any aspect of the present invention, the pharmaceutical composition comprises another therapeutic agent.

[0232] According to any aspect of the present invention, the therapeutic agent comprises an immunomodulatory agent.

[0233] According to any aspect of the present invention, the immunomodulator comprises an antibody or its antigen binding protein, binding fragment, receptor, ligand and / or compound or any combination thereof.

[0234] According to any aspect of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier.

[0235] In another aspect, the present application provides a use of the migrator described in the present application, the vaccine composition described in the present application, and / or the pharmaceutical composition described in the present application in the preparation of a drug for preventing and / or treating a disease.

[0236] According to any aspect of the present invention, the disease includes but is not limited to tumors.

[0237] According to any aspect of the present invention, the tumor includes but is not limited to solid tumors and / or hematological tumors.

[0238] In another aspect, the present application provides a use of the migrator described in the present application, the vaccine composition described in the present application, and / or the pharmaceutical composition described in the present application in preventing and / or treating a disease.

[0239] According to any aspect of the present invention, the disease includes but is not limited to tumors.

[0240] According to any aspect of the present invention, the disease includes but is not limited to solid tumors and / or hematological tumors.

[0241] In another aspect, the present application provides a method for preventing and / or treating a disease, comprising administering the migrator described in the present application, the vaccine composition described in the present application, and / or the pharmaceutical composition described in the present application to a subject in need thereof.

[0242] According to any aspect of the present invention, the disease includes but is not limited to tumors.

[0243] According to any aspect of the present invention, the tumor includes but is not limited to solid tumors and / or hematological tumors.

[0244] According to any aspect of the invention, the method comprises combining with one or more other therapeutic methods.

[0245] According to any aspect of the invention, the method comprises the use of an additional therapeutic agent.

[0246] According to any aspect of the present invention, the therapeutic agent comprises an immunomodulatory agent.

[0247] According to any aspect of the present invention, the immunomodulator comprises an antibody or its antigen binding protein, binding fragment, receptor, ligand and / or compound or any combination thereof.

[0248] Those skilled in the art can easily perceive other aspects and advantages of the present application from the detailed description below. In the detailed description below, only exemplary embodiments of the present application are shown and described. As will be appreciated by those skilled in the art, the content of the present application enables those skilled in the art to modify the disclosed specific embodiments without departing from the spirit and scope of the invention to which the present application relates. Accordingly, the description in the drawings and specification of the present application is merely exemplary and not restrictive. BRIEF DESCRIPTION OF THE DRAWINGS

[0249] The specific features of the invention involved in this application are shown in the attached claims. The features and advantages of the invention involved in this application can be better understood by referring to the exemplary embodiments and drawings described in detail below. A brief description of the drawings is as follows:

[0250] Figure 1 Shown are confocal micrographs of migrasomes prepared from MCA-205 cells as described herein.

[0251] Figure 2 Shown are confocal micrographs of migrasomes prepared from 4T1 cells as described herein.

[0252] Figure 3 Shown are confocal micrographs of migrasomes produced by primary human skin squamous cell carcinoma cells cultured as described herein.

[0253] Figure 4 Shown are Western Blot detection results of migrasomes prepared from 4T1 cells and migrasomes prepared from MCA-205 cells described in the present application.

[0254] Figure 5 The percentage of APC_HLA positive among WGA-AF488 positive migratory bodies under flow cytometry is shown.

[0255] Figure 6 The results of staining MC38-OVA cell migratory bodies using Tspan4-GFP, WGA, and H2Kb-IINFEKL-APC antibodies are shown.

[0256] Figure 7 It is shown that the migratoria prepared from MCA-205 cells described in the present application can activate T cell immunity in vivo.

[0257] Figure 8 Shown is the anti-tumor effect of the migrasome prepared from 4T1 cells described in the present application in the 4T1 tumor model.

[0258] Fig. 9 Shown is the anti-tumor effect of the migrasome prepared from MCA-205 cells described in the present application in the MCA-205 tumor model.

[0259] Fig.10 Tumor volumes after injection of migrasome vaccine and tumor cell lysate are shown.

[0260] Fig.11 Shown are the tumor volumes of mice immunized with the migrasome tumor vaccine after re-inoculation with the tumor. DETAILED DESCRIPTION

[0261] The following is an explanation of the implementation of the present invention by means of specific embodiments. Those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.

[0262] Definition of terms

[0263] In the present application, the term "migrasome" generally refers to a structure generated by a cell when relative displacement occurs. For example, a migrasome may be a new type of organelle. For example, a vesicle structure may be generated at the tip or intersection of contractile filaments left at the tail of a cell during cell migration. For example, during cell migration, the cell body continuously transports intracellular substances to the migrasome, and then the contractile filaments break, and the migrasome is released, which may be transported to distal tissues at the local site where it is produced or through body fluids such as blood, and then taken up by the extracellular space or surrounding cells. For example, a migrasome may be involved in the transmission of intracellular substances and signals between cells, thereby mediating intercellular communication.

[0264] In the present application, the term "engineered migrator" is a migrator produced by inducing relative displacement of cells by physical and / or chemical treatment of cells in vitro. For example, the engineered migrator contains proteins of the tetraspanin family. For example, the engineered migrator is a vesicle-like structure composed of an outer lipid membrane and contents, and its lipid membrane components include cholesterol, phospholipids, sphingomyelin, etc. For example, the engineered migrator may not contain a cell nucleus. For example, the engineered migrator can be produced by a cultured cell line or by a primary cell.

[0265] In the present application, the term "antigen" is used interchangeably with the term "immunogen" and generally refers to a substance that can induce an immune response. For example, an antigen may include any molecule or composition that can stimulate or enhance any immune response indicator. Immune response indicators include, but are not limited to, any of the following immune activities: the production of cytokines, antibodies and / or other active molecules, the production of antibodies, the activation of immune cells, the expansion of immune cells, the proliferation of immune cells, the cytotoxicity mediated by immune cells, and changes in the expression of immune cell surface markers. For example, an antigen may include a protein, a peptide, a polysaccharide, a lipopolysaccharide, a lipopeptide or other molecule; or it may be any combination of the above. For example, an antigen may include a protein or a protein fragment or a polypeptide fragment; it may also include a glycoprotein, a glycopeptide, a lipoprotein, a lipopeptide, a nuclear protein, a nuclear polypeptide; it may also include a conjugate of a polypeptide and a polypeptide; or it may also include a recombinant nucleic acid expression product. For example, an antigen may include an epitope. In the present application, the term "epitope" is a portion of a given substance (e.g., an antigenic molecule or an antigenic complex) that determines its immunological specificity.

[0266] In this application, the term "endogenous" generally refers to any substance originating from or produced in an organism, cell, tissue, organ or system.

[0267] In this application, the term "tumor" generally refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues. The terms "cancer", "cancerous", "cell proliferative disorders", "proliferative disorders", "malignant tumors" and "tumors" are not mutually exclusive when mentioned herein. In some embodiments, a tumor may refer to a mass of flesh containing a majority of cancer / malignant tumor cells, such as cells that show the characteristics of any tumor described herein. Examples of tumors may include primary tumors of any of the above types of malignant tumors or metastatic tumors at a second site derived from any of the above types of malignant tumors. Examples of tumors include solid tumors and hematological tumors.

[0268] In this application, the term "tumor cell" generally refers to a cell that constitutes a tumor component in a subject, or a cell that is determined to be prone to becoming a tumor component, that is, a cell that is a component of a precancerous lesion in a subject.

[0269] In the present application, the term "tumor antigen" generally refers to any molecule carried by tumor cells that can induce the body to produce an anti-tumor immune response. For example, some tumor antigens may be known or believed to contribute to the tumorigenesis of tumor cells. For example, some tumor antigens may include any molecule expressed on tumor cells (or associated with tumor cell development), known or believed to have an effect on the tumorigenic properties of tumor cells. For example, many tumor antigens are known in the art. For example, whether a molecule is a tumor antigen can also be determined according to techniques and assays well known to those skilled in the art, such as clonogenic assays, transformation assays, in vitro or in vivo tumor formation assays, gel migration assays, gene knockout analysis, etc. For example, some tumor antigens may be presented on the cell surface, with an extracellular portion that is usually combined with the transmembrane and cytoplasmic portions of the molecule. For example, some tumor antigens may not be related to tumor development, known or believed to have no effect on the tumorigenic properties of tumor cells. For example, some tumor antigens may not have the function of promoting tumors. For example, the expression of tumor antigens in tumor cells may be different from that in normal cells. For example, some tumor antigens may include any molecule that can be used as a tumor marker. For example, tumor antigens may sometimes be presented only by tumor cells and never by normal cells. For example, tumor antigens may be expressed exclusively on tumor cells or may represent tumor-specific mutations compared to normal cells. For example, tumor antigens may include viral antigens expressed in tumors, such as antigens produced by hepatitis B virus in tumor cells, antigens produced by human papillomavirus, and antigens produced by human herpes virus type 4 (also known as Epstein-Barr virus). In this case, they are called tumor-specific antigens. For example, tumor antigens may also include molecules whose expression levels in tumor tissues are higher than those in normal tissues, and they are called tumor-associated antigens. Under normal circumstances, normal cells of adult organisms do not express or express at a low level, or only express in embryonic periods and / or specific organs, but express or overexpress in tumor cells, or because tumor tissues have a less compact structure than normal tissues, they are easily combined with antibodies or immune cells in tumor cells. For example, tumor antigens include antigens that have been identified and also include antigens that have not yet been identified but can cause an immune response.

[0270] In this application, the term "tumor cell antigen" generally refers to any substance in a tumor cell that can elicit an immune response. This definition includes, but is not limited to, intact tumor cells containing all relevant antigens as antigens, as well as any component of the cell, such as proteins in the plasma membrane, cell surface or membrane, or unique carbohydrate motifs associated with the cell surface. This definition also includes those antigens from cells that require special treatment of the cells to obtain.

[0271] In the present application, the term "universal tumor antigen" generally refers to an immunogenic molecule (such as a protein) that is expressed at a higher level in tumor cells than in non-tumor cells and is also expressed in tumors of different origins. For example, a universal tumor antigen may include a tumor antigen that is present in multiple patients. For example, a universal tumor antigen may include a specific tumor-associated antigen and a tumor-specific antigen. For example, a universal tumor antigen is expressed in more than about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or more of malignant tumors (e.g., human malignant tumors). For example, a universal tumor antigen may be expressed in non-tumor cells (e.g., normal cells), but at a level lower than that expressed in tumor cells. For example, the expression level of a universal tumor antigen on tumor cells is about 1 times, about 2 times, about 3 times, about 4 times, about 5 times, about 6 times, about 7 times, about 8 times, about 9 times, about 10 times or more than that on non-tumor cells. For example, a universal tumor antigen is not expressed in normal cells and is only expressed in tumor cells.

[0272] In the present application, the term "neoantigen" generally refers to a tumor antigen that is specific to a specific subject. For example, a neoantigen may include an antigen that does not exist in a normal body and is newly produced in a tumor due to a gene mutation. For example, a neoantigen may also include a tumor antigen of a specific type of tumor of a specific subject. For example, a neoantigen may include an antigen encoded by a tumor-specific mutant gene.

[0273] In the present application, the term "anti-tumor" or "anti-tumor effect" generally refers to a biological effect that can be manifested in various ways, including but not limited to, for example, a reduction in the number of tumor cells, a reduction in tumor cell proliferation, a reduction in tumor cell survival, a reduction in tumor volume, a reduction in the number of metastases, an increase in life expectancy, or an improvement in various physiological symptoms associated with cancerous conditions, prevention of tumor recurrence / reduction of tumor recurrence rate.

[0274] In this application, the term "antigen presentation" generally refers to the process of displaying processed antigen peptides on the cell surface.

[0275] In this application, the term "MHC (major histocompatibility complex)", also known as "major histocompatibility complex", "major histocompatibility complex gene", generally refers to a group of genes encoding animal major histocompatibility antigens. In this application, "MHC molecules", also known as "major histocompatibility antigens", generally refer to the encoded products of MHC. The MHC gene family is divided into three subgroups, encoding three types of molecules: MHC class I molecules, MHC class II molecules, and MHC class III molecules. In humans, these MHC molecules are called human leukocyte antigens (human leukocyte antigen, HLA), and the genes of the HLA locus are located on the short arm of chromosome 6.

[0276] In this application, the term "MHC-peptide complex" or "peptide-MHC complex" or variants thereof generally refers to the binding or complex of a peptide antigen and an MHC molecule, such as, generally through non-covalent interaction of the peptide in the binding groove or cleft of the MHC molecule. In some embodiments, the MHC-peptide complex is presented or displayed on the cell surface. For example, the MHC-peptide complex can be specifically recognized by an antigen receptor, such as a TCR, a TCR-like CAR, or an antigen binding portion thereof.

[0277] In the present application, the term "immune co-stimulatory molecule" generally refers to a cell surface molecule other than a T cell receptor, a B cell receptor and / or an identified antigen required for an effective immune response. For example, an immune co-stimulatory molecule may include a ligand that binds to a corresponding binding receptor on an immune cell, and mediates immune cells to participate in an immune response. For example, an immune co-stimulatory molecule may cause the initiation, maintenance and long-term memory of an immune response. For example, an immune co-stimulatory molecule may relate to a natural interaction between a naive T cell and an antigen presenting cell, which results in mutual activation and promotes the expression of various cell surface ligands and receptors. For example, an immune co-stimulatory molecule may include a T cell co-stimulatory molecule.

[0278] In the present application, the term "immune response" generally refers to the body's defense response to foreign components or mutated self components. For example, the immune response may involve any one or more of the following responses: cellular immune response, humoral immune response, specific immune response, nonspecific immune response, specific and nonspecific response, innate immune response, primary immune response, adaptive immunity, secondary immune response, memory immune response, immune cell activation, immune cell proliferation, immune cell differentiation, immune cell-mediated cytotoxicity and cytokine expression.

[0279] In this application, the term "personalized" generally refers to the individual level (a specific subject) or the subpopulation level (a small group of people who share the same characteristics, for example, have a specific disease, characteristic phenotypic characteristics (including but not limited to a specific MHC molecule type), or take the same medication or show the same defects (for example, in the immune system)).

[0280] In this application, the term "relative displacement" generally refers to displacement relative to a reference point or reference surface. It refers to the displacement of the cell center relative to the environment (such as the attached surface), or when the cell center is stationary, the relative displacement of its membrane surface relative to the surrounding microenvironment (such as the attached solid surface, or the liquid phase in the microenvironment) or relative to the cell center (such as expansion, deformation from flat to bulge, etc.).

[0281] In this application, the term "membrane microdomain" generally refers to a region having a biological membrane structure, for example, a microdomain of a cell membrane based on sphingolipids and cholesterol (Ch), including lipid rafts, Tetraspanin-enriched microdomain (TEM), etc.

[0282] In this application, the term "intraluminal vesicle" generally refers to a membranous vesicle (e.g., an organelle or larger vesicle) formed or present in a lumen or space of a lumen or tubular structure. Lumen (lumen) can also be used herein to describe the internal space of a cellular component or structure. For example, an intraluminal vesicle can be produced by an organelle. For example, an intraluminal vesicle can include an intraluminal vesicle in a migrator, or an intraluminal vesicle that is not currently in a migrator but is expected to be transferred into a migrator.

[0283] In the present application, the term "Tetraspanin" is generally a tetraspanin superfamily, which comprises four transmembrane domains. These proteins can form so-called tetraspanin-enriched microdomains (TEMs) (Rubinstein, E. (2011). The complexity of tetraspanins. Biochem Soc Trans 39, 501-505.). TEMs are about 100 nanometers in size and are rich in a series of proteins and lipid rafts, such as cholesterol. During the formation of the migratory body, many small TEMs will gather to form micron-scale macrodomains, called tetraspanin-enriched macrodomains (TEMAs), and the formation of TEMAs can be related to the growth of the migratory body on the contractile filaments. For example, the Tetraspanin family can include 33 members, including Tspan1, Tspan2, Tspan3, Tspan4, Tspan5, Tspan6, Tspan7, Tspan8, Tspan9, Tspan10, Tspan11, Tspan12, Tspan13, Tspan14, Tspan15, Tspan16, Tspan17, Tspan18, Tspan19, Tspan Tetraspanin family members include Tspan20 (UPK1B), Tspan21 (UPK1A), Tspan22 (PRPH2), Tspan23 (ROM1), Tspan24 (CD151), Tspan25 (CD53), Tspan26 (CD37), Tspan27 (CD82), Tspan28 (CD81), Tspan29 (CD9), Tspan30 (CD63), Tspan31, Tspan32, and Tspan33. Data from biochemical studies and knockout mice indicate that these tetraspanin family members play important roles in membrane biology.

[0284] In the present application, the term "prevention and / or treatment" includes not only prevention and / or treatment of diseases, but also generally includes prevention of the onset of diseases, slowing or reversing the progression of diseases, preventing or slowing the onset of one or more symptoms associated with diseases, reducing and / or alleviating one or more symptoms associated with diseases, reducing the severity and / or duration of diseases and / or any symptoms associated therewith, and / or preventing further increase in the severity of diseases and / or any symptoms associated therewith, preventing, reducing or reversing any physiological damage caused by diseases, and any pharmacological effects that are generally beneficial to patients being treated. The compositions of the present application form viable therapeutic agents that do not require complete cure or eradication of any symptoms or manifestations of the disease. As recognized in the relevant art, drugs used as therapeutic agents can reduce the severity of a given disease state, but do not need to eliminate every manifestation of the disease to be considered a useful therapeutic agent. Similarly, prophylactically administered treatments constitute viable preventive agents that do not need to completely and effectively prevent the onset of the disease. It is sufficient to simply reduce the impact of the disease in the subject (e.g., by reducing the number or severity of its symptoms, or by increasing the effectiveness of another treatment, or by producing another beneficial effect), or reduce the likelihood of disease occurrence or exacerbation.

[0285] In the present application, the term "vaccine composition" generally refers to a drug used to stimulate the body to produce an immune response to reduce existing damage or protect the body from further damage. In the present application, the vaccine composition comprises a therapeutically effective amount of one or more migratory bodies of the present application. In the present application, the vaccine composition may also include other immunologically active ingredients, which can simultaneously cause the body to produce multiple immune responses. In the present application, the vaccine composition may also include an immune adjuvant.

[0286] In the present application, the term "immune adjuvant" generally refers to a substance that acts to accelerate, prolong or enhance the quality of a specific immune response to an antigen.

[0287] In the present application, the term "pharmaceutical composition" generally refers to a preparation in a form that allows the biological activity of the active ingredient to be effective, and it does not contain other ingredients that have unacceptable toxicity to the subject to be administered with the preparation. In the present application, the pharmaceutical composition comprises one or more of the migrators of the present application of a therapeutically effective amount. In the present application, the pharmaceutical composition may also comprise the suitable preparation of one or more (pharmaceutically effective) carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers, preservatives and / or adjuvants. In the present application, the pharmaceutical composition may also comprise other therapeutic agents.

[0288] In the present application, the term "therapeutically effective amount" refers to the amount of therapeutic agent required to treat, improve or prevent a targeted disease or condition or to exhibit a detectable therapeutic or preventive effect. For any migratory body described in the present application, the therapeutically effective amount can be initially estimated in a cell culture assay or in an animal model, usually in a rodent, rabbit, dog, pig or primate. The animal model can also be used to determine the appropriate concentration range and route for administration. The information can then be used to determine the dosage and route suitable for administration to a human. The precise therapeutically effective amount of a human subject will depend on the severity of the disease condition, the overall health of the subject, the age, weight and sex of the subject, diet, time and frequency of administration, drug combination, reaction sensitivity and tolerance / reaction to therapy.

[0289] In this application, the terms "subject", "individual", "body" and the like are used interchangeably herein and refer to any organism, or cells or tissues thereof, whether in vitro or in situ, suitable for the methods described herein. In this application, the term "patient" may include a person in need of treatment for a malignant tumor, or a precancerous condition or injury.

[0290] In this application, the term "sample" generally refers to biological material from a subject. The sample used in the present invention is not limited to any particular type. As non-limiting examples, samples include single cells, multiple cells, tissues, tumors, biological fluids, biomolecules, or any of the aforementioned supernatants or extracts. The sample of the present invention may include biological materials that have been separated and / or cultured after removal. For example, the sample may include isolated cells, which may be obtained from body fluids or tissues or organs by separation techniques such as centrifugation or cell sorting. For example, the sample may also include cells obtained by amplification or in vitro culture of isolated cells.

[0291] In the present application, the term "directly genetically modified" generally refers to modifying cells to express exogenous antigens. For example, the expression of exogenous antigens may include expression on the genome of the cell and expression in the form of a vector. Cells not directly genetically modified as described in the present application may include cells that do not express exogenous antigens.

[0292] In the present application, the term "exogenous" generally refers to any material introduced from an organism, cell, tissue or system or produced outside an organism, cell, tissue or system. In the present application, the term "exogenous" used to describe a nucleotide sequence or protein generally refers to the position where the nucleic acid or protein is not naturally present in a chromosome or a host cell. Exogenous nucleic acid sequences can also refer to sequences derived from and inserted into the same host cell or experimenter, but they exist in a non-natural state, such as different copy numbers or under the control of different regulatory elements.

[0293] In this application, the term "about" generally refers to variations within a range of 0.5%-20% above or below a specified value, for example, about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20% above or below a specified value. DETAILED DESCRIPTION OF THE INVENTION

[0295] Induce and / or modulate immune responses

[0296] In one aspect, the present application provides a migrator-activated protein molecule capable of inducing and / or regulating an immune response.

[0297] For example, the immune response may include an innate immune response, a humoral immune response, a cell-mediated immune response, or a combination thereof. For example, the immune response may include the production of cytokines, antibodies, and / or other active molecules, the production of antibodies, the activation of immune cells, the morphological changes of immune cells, the amplification of immune cells, the proliferation of immune cells, the cytotoxicity mediated by immune cells, and the changes in the expression of immune cell surface markers and internal active substances. For example, the immune response may include increasing the killing function of immune cells. For example, the immune response may include an anti-tumor response. For example, the immune response may include inducing immune memory. For example, the immune response may include immune cell infiltration of tumors.

[0298] For example, the immune response may include a cellular immune response. For example, the cellular immune response may include a T cell-mediated immune response. For example, the cellular immune response may include a CD4 + T cell response and / or CD8 + T cell response.

[0299] For example, the immune response may include a humoral immune response. For example, the humoral immune response may include the production of antibodies. For example, the humoral immune response may include an immune response in which effector B cells participate. For example, the humoral immune response may include inducing immune memory.

[0300] For example, the immune response includes promoting activation of antigen presenting cells, increasing antigen presentation and / or cytokine release. Antigen presenting cells include but are not limited to dendritic cells, macrophages, monocytes, B cells.

[0301] For example, the migratory body described in the present application can induce an immune response. For example, the migratory body described in the present application can regulate an immune response. For example, the migratory body described in the present application can raise the level of an immune response. For example, compared with before the application of the migratory body and / or with a reference not applying the migratory body, the immune response level increases by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more. For example, the level of the immune response can be detected and / or analyzed by technical means known in the art. For example, the immune response can include activated immune cells. For example, the immune response can include the activation of induced immune cells.

[0302] For example, the immune cell may include all cells involved in an immune response. For example, the immune cell may include lymphocytes. For example, the immune cell may include B cells and / or T cells. For example, the immune cell may include natural killer cells. For example, the immune cell may include myeloid cells. For example, the immune cell may include monocytes, macrophages, eosinophils, mast cells, basophils and / or neutrophils. For example, the immune cell may include antigen presenting cells. For example, the antigen presenting cells may include dendritic cells, macrophages, monocytes and / or B cells.

[0303] For example, the activation and / or induction of immune cell activation may include the expression and / or upregulation of immune cell activation molecules. For example, the activation and / or induction of immune cell activation may include the expression and / or upregulation of T cell activation molecules, B cell activation molecules, NK cell activation molecules and / or antigen presenting cell activation molecules. For example, the activation molecules may include but are not limited to CD80, CD86, MHC, CD25 and / or CD69. For example, compared with the reference before the application of the migrator and / or without the application of the migrator, the expression level of the immune cell activation molecule is increased by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more. For example, the activation and / or induction of immune cell activation may include the morphological changes of immune cells. For example, the morphological changes of the immune cells may include the morphological changes of T cells, B cells, NK cells and / or antigen presenting cells. For example, the morphology of the immune cells may include the enlargement of the cell volume. For example, the morphology of the immune cell changes compared to before administration of the migrator and / or compared to a reference without administration of the migrator. For example, the morphology change can be detected by optical imaging.

[0304] For example, the activation and / or induction of immune cell activation may include changes in the number of immune cells. For example, the changes in the number of immune cells may include changes in the number of T cells, B cells, NK cells and / or antigen presenting cells. For example, the activation and / or induction of immune cell activation may include the amplification or proliferation of immune cells. For example, compared with before the application of the migrator and / or with a reference not applying the migrator, the number of immune cells increased by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more. For example, the activation and / or induction of immune cell activation may also include the cessation of immune cell amplification or proliferation. For example, the number of immune cells may be detected by technical means known in the art.

[0305] For example, the activation and / or induction of immune cell activation may include changes in the expression of adhesion molecules on the surface of immune cells and / or other molecules involved in immune cell homing. For example, the expression changes of the adhesion molecules and / or other molecules involved in immune cell homing may include and are not limited to CD62L, CD2 / CD58 (LFA-3), LFA-1 / ICAM-1, ICAM-3 / CD209, CD4 / MHC class II molecules, CD8 sub / MHC class I sub, CD28 / B7, CD40L / CD40 expression up-regulation or down-regulation. For example, compared to before the application of the migrator and / or compared to a reference in which the migrator is not applied, the expression of adhesion molecules and / or other molecules involved in immune cell homing of the immune cells increases or decreases by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more.

[0306] The activation and / or induction of immune cell activation may include changes in immune cell distribution. For example, the changes in immune cell distribution may include changes in the distribution and / or proportion of different subtypes of T cells, B cells, NK cells and / or antigen presenting cells in peripheral blood, lymphoid organs and diseased tissues. For example, compared to before the application of the migrator and / or compared to a reference without the application of the migrator, the changes in immune cell distribution may include an increase in the distribution of different subtypes of T cells, B cells, NK cells and / or antigen presenting cells in diseased tissues (including but not limited to inflammation, tumors, pathogenic microorganisms, and trauma) by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more.

[0307] For example, the immune response may include the production and / or secretion of antibodies, cytokines and / or other active molecules. For example, the induced immune response may include the production and / or secretion of cytokines, antibodies and / or other active molecules. For example, the cytokines may include, but are not limited to, interleukins, interferons, chemokines, hematopoietic growth factors, tumor necrosis factors and / or transforming growth factors. For example, the cytokines may include, but are not limited to, interferons (IFN). For example, the interferons may include, but are not limited to, IFNγ. For example, compared to before the application of the migrator and / or compared to a reference not applying the migrator, the production and / or secretion of the cytokines, antibodies and / or other active molecules increases by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more.

[0308] For example, the immune response may include increasing the killing function of immune cells. For example, the killing function of the enhanced immune cells may include increasing the generation and / or release of substances that mediate cell killing. For example, the substances that mediate cell killing include but are not limited to perforin and / or granzyme. For example, compared with before applying the migrator and / or with a reference that does not apply the migrator, the generation and / or release of the substances that mediate cell killing increases by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more.

[0309] For example, the immune response may include inducing immune memory. For example, the immune memory may include recognizing an antigen previously encountered by the body and initiating a corresponding immune response. For example, the immune memory may include the generation or increase of memory T cells and / or memory B cells. For example, compared to before the migrator is applied and / or compared to a reference not applying the migrator, the number of memory T cells and / or memory B cells increases by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more.

[0310] For example, the immunological memory may include an immune response initiated by recognition of the migrator and / or an antigen possessed by the migrator.

[0311] For example, the immune response may include increasing the immune cell infiltration of the tumor. For example, the increase in the immune cell infiltration of the tumor may include increasing the content and / or quantity of immune cells in the tumor microenvironment. For example, the immune cells in the tumor microenvironment may include tumor infiltrating immune cells. For example, the tumor infiltrating immune cells may include T cells, B cells, NK cells, macrophages, neutrophils, dendritic (DC) cells, mast cells, eosinophils and / or basophils. For example, compared to before the application of the migrator and / or compared to a reference not applying the migrator, the content and / or quantity of immune cells in the tumor microenvironment increases by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100% or more.

[0312] For example, the immune response may include an anti-tumor response. For example, the anti-tumor response may include a response that reduces the number of tumor cells, reduces tumor cell proliferation, reduces tumor cell survival, reduces tumor volume, reduces the number of metastases, reduces metastatic tumor volume, increases life expectancy, or improves various physiological symptoms associated with cancerous conditions. For example, the anti-tumor response may include preventing tumors or preventing tumors. For example, the anti-tumor response may include preventing the metastasis and / or recurrence of a tumor. For example, the anti-tumor response may include and / or reduce the metastasis and / or recurrence rate of a tumor.

[0313] In some embodiments, the migrator described in the present application can directly induce and / or regulate immune response. In some embodiments, the migrator described in the present application does not require the participation of antigen presenting cells to induce and / or regulate immune response. In some embodiments, the migrator described in the present application can directly activate or activate immune cells. In some embodiments, the migrator described in the present application can directly activate or activate immune cells. For example, the migrator described in the present application can directly activate B cells and / or T cells. In some embodiments, the migrator can directly interact with the T cell receptor (TCR) of T cells.

[0314] In some embodiments, the migrator can indirectly induce and / or regulate an immune response. In some embodiments, the migrator needs the participation of antigen presenting cells to induce and / or regulate an immune response. In some embodiments, the migrator described in the present application can indirectly activate or activate immune cells. In some embodiments, the migrator described in the present application can indirectly activate or activate immune cells. For example, the migrator described in the present application can indirectly activate B cells and / or T cells. In some embodiments, the migrator may not directly interact with the T cell receptor (TCR) of T cells. For example, the migrator can activate antigen presenting cells, such as activating one or more of DC cells, macrophages, monocytes, and B cells. For example, the antigen carried by the migrator can be processed and presented by antigen presenting cells.

[0315] antigen

[0316] In another aspect, the present application provides a migrating body, which may contain an antigen.

[0317] For example, the migrating body described herein may contain an antigen, and the antigen may be present on the surface and / or inside the migrating body. For example, the antigen may be present in the membrane of the migrating body. For example, the antigen may be present in the lumen of the migrating body and / or in an intraluminal vesicle.

[0318] For example, the antigen in the migration body described in the present application can include endogenous or exogenous antigens.For example, the antigen can include any antigen from organism, cell, tissue, organ or system, or any antigen produced and / or loaded in organism, cell, tissue, organ or system.For example, the antigen can derive from any antigen of human body, human cell, human tissue, human organ or human system, or any antigen produced and / or artificially synthesized in human body, human cell, human tissue, human organ or human system.For example, the antigen can derive from any antigen of mouse, mouse cell, mouse tissue, mouse organ or mouse system, or any antigen produced and / or artificially synthesized in mouse body, mouse cell, mouse tissue or mouse system.For example, the antigen can include antigen derived from bacterium, virus, fungus, protozoa or its combination in any.

[0319] For example, the antigens in the migrator described in the present application may include cell endogenous antigens. For example, the cell endogenous antigens may include, but are not limited to, cells containing all relevant antigens as antigens, and any component in the cell as antigens. For example, the cell endogenous antigens may include, but are not limited to, infected cells containing all relevant antigens as antigens, and any component in the infected cells as antigens.

[0320] For example, the migrator described in the present application may include a tumor antigen. For example, the antigen may include any antigen from a tumor patient, tumor cell, or tumor tissue. For example, the antigen may include any antigen produced in a tumor patient, tumor cell, or tumor tissue. For example, the antigen may be from a viral antigen carried in a tumor cell.

[0321] For example, the tumor antigen may include a tumor cell antigen. For example, the tumor cell antigen may include, but is not limited to, a tumor cell containing all relevant antigens as an antigen, and any component in a tumor cell as an antigen.

[0322] For example, the migratory body described in the present application may contain tumor-specific antigens, tumor neoantigens, tumor-fetal antigens, tumor-testis antigens and / or tumor-related antigens. For example, the migratory body described in the present application may contain tumor neoantigens. For example, the migratory body described in the present application may contain different types of tumor antigens. For example, the migratory body described in the present application may contain universal tumor antigens. For example, non-limiting examples of universal tumor antigens described in the present application include the following proteins and peptides derived from the following proteins and products of gene mutations of the following proteins: KRAS (Kirsten ratsarcoma viral oncogene homolog), programmed death protein and its ligand 1, ligand 2 (PD-1, PD-L1, PD-L2), cMET, EGFR (epidermal growth factor receptor), HER2 (human epidermal growth factor receptor 2), ERBB2, LMP1 protein of human herpesvirus type 4, LMP2 protein of human herpesvirus type 4, E6 protein and / or E7 protein of human papillomavirus (HPV), MAGE family proteins such as MAGE-A1, MAGE-A3 (Melanoma-associated antigen 3), GAGE ​​family proteins, BAGE family proteins, NY-ESO-1 (New York esophageal squamous cell carcinoma 1), gp100 (also known as premelanosome protein, PMEL), IDO (indoleamine 2,3-dioxygenase 1, indoleamine 2,3-dioxygenase 1), MART1 (melanoma antigen recognized by T cells 1), TAG-72 (Tumor-associated glycoprotein 72), ganglioside GD2, endothelial lining antigens in tumor vasculature, mesothelin, VEGFR, α-folate receptor, CE7R, testicular cancer antigen, survivin, tumor protein D52 (TPD52), androgen receptor, ephrin type A receptor 2 (EphA2), human telomerase reverse transcriptase (hTERT), mouse double minute 2 homolog (mouse double minute 2 homolog) (MDM2), cytochrome P450 1B1 (CYP1B), Wilms tumor gene 1 (WT1), survival protein (livin), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), epithelial tumor antigen (ETA), mucin 1 (MUC1), Tn-MUC1, mucin 2 (MUC2), mucin 16 (MUC16), prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), PAP (Prostatic acid phosphatase, prostatic acid phosphatase), p53 or cell cycle protein (D1) or any combination thereof, carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 242 (CA242), EpCAM, epithelial cell adhesion molecule (ECAM), carcinoembryonic antigen-related cell adhesion molecule (CEACAM), PRAME.

[0323] For example, the tumor antigens described in the present application may include but are not limited to one or more or any combination of the above-mentioned universal tumor antigens and neo-tumor antigens.

[0324] For example, the migrator described in the present application may contain antigens derived from cells infected with microorganisms. For example, the antigens may include herpes viruses (such as human gamma herpes virus 4 (Epstein-Barr virus, EBV), herpes simplex virus 2 (HSV2), human herpes virus 8), influenza A, influenza B, cytomegalovirus, respiratory syncytial virus (RSV), HIV (e.g., HIV-2), coronaviruses (e.g., Coronavirus, MERS-CoV, SARSCoV, SARS CoV-2), filoviruses (e.g., Marburg virus and Ebola virus), chikungunya virus, human papillomavirus (HPV), hepatitis viruses (A, B, C, D, E), Merkel cell polyomavirus (MCV), bunyaviruses (e.g., hantavirus), arenaviruses (e.g., LCMV virus and Lassa virus), flaviviruses (e.g., dengue virus, Zika virus, Japanese encephalitis virus, West Nile virus, and yellow fever virus), enteroviruses (e.g., poliovirus), astroviruses (e.g., gastroenteritis virus, , Rhabdoviridae (e.g., rabies virus), adenovirus, adeno-associated virus (AAV), Borrelia borrelii and Borrelia mayo (e.g., Lyme disease), Staphylococcus aureus, Mycobacterium tuberculosis, Klebsiella spp., Pseudomonas aeruginosa, Enterococcus spp., Proteus spp., Enterobacter spp., Actinomyces spp., coagulase-negative Staphylococcus spp. (CoNS), Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma spp., Chlamydia trachomatis, Plasmodium spp. (e.g., Plasmodium vivax and Plasmodium falciparum), or a combination thereof.

[0325] For example, antigens in the migratory body can be directly or indirectly detected and / or analyzed by technical means known in the art. For example, the migratory body described in the present application can contain at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different antigens. For example, the antigens in the migratory body described in the present application can be detected and / or analyzed by immune response indicators. For example, immune response indicators include but are not limited to any one or more of the following immune activities: the production of cytokines, antibodies and / or other active molecules, the production of antibodies, the activation of immune cells, the morphological changes of immune cells, the amplification of immune cells, the proliferation of immune cells, the cytotoxicity mediated by immune cells and the changes in the expression of immune cell surface markers. For example, after the application of the migratory body, the appearance and / or improvement of the immune response index before application can indicate that the migratory body contains the antigen. For example, relative to the reference group not using the migratory body, the immune response index of the experimental group applying the migratory body appears and / or improves, which can indicate that the migratory body contains the antigen.

[0326] In the present application, the antigens in the migsomes can be personalized. In certain embodiments, whether or not to detect and / or analyze the antigens in the migsomes does not affect the function and / or effect of the migsomes. For example, the effect of the migsomes inducing and / or regulating immune responses is not affected by not detecting the antigen type and / or the number of antigen molecules in the migsomes.

[0327] Molecules involved in antigen presentation

[0328] In another aspect, the present application provides a migrating body, which may contain molecules involved in antigen presentation.

[0329] For example, the migrating body described in the present application may contain a molecule involved in antigen presentation, and the molecule involved in antigen presentation may be present on the surface of the migrating body. For example, the molecule involved in antigen presentation may be present in the membrane of the migrating body.

[0330] For example, the molecules involved in antigen presentation may include major histocompatibility complex (MHC) and / or immune co-stimulatory molecules.

[0331] For example, the migrator may contain an MHC molecule. For example, the MHC molecule may include an MHC class I molecule, an MHC class II molecule, and / or an MHC class III molecule.

[0332] For example, the migrator may contain one or more or any combination of immune co-stimulatory molecules and / or adhesion molecules and / or their ligands. For example, the immune co-stimulatory molecules and / or adhesion molecules may include but are not limited to MHC class I molecules, TNF superfamily proteins, TNF receptor superfamily proteins, immunoglobulin superfamily proteins, cytokine receptors, integrins, signal lymphocyte activation molecules (SLAM proteins), NK cell activation receptors, BTLA, Toll-like receptors (TLRs), cGAS / STING; specifically including but not limited to OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD80, CD86, CDS, ICAM-1, 4-1BB (CD137), CDS, ICOS (CD278), GITR, BAFFR, LIGHT, HVE M(LIGHTR), KIRDS2, SLAMF7, NKp80(KLRF1), NKp44, NKp30, NKp46, CD19, CD20, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, integrin n, ITG; such as ITGA4, ITGA5, ITGA6, ITGAv, ITGAD, ITGAE, ITGAL, ITGAM, ITGAX, ITGB1, ITGB2, ITGB7,); VLA1, CD49a, IA4, CD49D, VLA-6, C D49f, CD11d, CD103, CD11a, LFA-1(CD11a / CD18), CD11b, CD11c, CD29, CD18, CD112, CD155, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DN AM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEACAM1, CRTAM, Ly9(CD229), CD160(BY55), PSGL1, CD100(SEMA4D), CD69 , SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, CD19a, and ligands that specifically bind to CD3, ligands that specifically bind to CD27, ligands that specifically bind to CD28, ligands that specifically bind to CD226, ligands that specifically bind to HVEM, ligands that specifically bind to CD40L, ligands that specifically bind to OX40, and ligands that specifically bind to 4-1BB.

[0333] For example, the migratory body can include an MHC-peptide complex or a variant thereof. For example, the MHC-peptide complex or a variant thereof is on the surface of the migratory body. For example, the MHC-peptide complex or a variant thereof is present in the membrane of the migratory body. For example, the MHC-peptide complex or a variant thereof can include an MHC class I molecule-peptide complex or a variant thereof. For example, the MHC-peptide complex or a variant thereof can include an MHC class II molecule-peptide complex or a variant thereof. For example, the migratory body described in the present application can activate immune cells by the MHC-peptide complex or a variant thereof. In some embodiments, the migratory body can directly interact with the T cell receptor (TCR) of the T cell through the MHC-peptide complex that the migratory body has.

[0334] For example, the molecules involved in antigen presentation in the migrator can be directly or indirectly detected and / or analyzed by techniques known in the art. For example, the migrator described herein can contain at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different molecules involved in antigen presentation.

[0335] In the present application, the molecules involved in antigen presentation in the migrator can be personalized. In some embodiments, whether to detect and / or analyze the molecules involved in antigen presentation in the migrator does not affect the function and / or effect of the migrator. For example, the type of molecules involved in antigen presentation and / or the number of molecules involved in antigen presentation in the migrator are not detected, and the effect of the migrator inducing and / or regulating immune response is not affected.

[0336] In some embodiments, the migrator may present antigens indirectly, for example, the antigens of the migrator may be phagocytosed by antigen-presenting cells, processed, and then presented on the surface of antigen-presenting cells.

[0337] Migrasomes are generated from cells

[0338] In the present application, the migrator can be generated from the corresponding cells. For example, the migrator can be generated from tissues or ex vivo cells.

[0339] For example, the migrator described in the present application can be produced from living cells. For example, the migrator described in the present application can be produced from cells with vital signs. For example, the migrator described in the present application can be produced from cells that can migrate, metabolize and / or reproduce and / or replicate. For example, the generation of the migrator described in the present application does not require inducing apoptosis in cells. For example, the cell can produce the migrator described in the present application without being irradiated.

[0340] For example, the migrator described in the present application can be produced from cells cultured in vitro. For example, the migrator described in the present application can be produced from cell lines, primary cells and / or cells and / or organoids through limited passage. For example, the migrator described in the present application can be produced from cells cultured in suspension or cultured by adherence. For example, the migrator described in the present application can be produced from cells from tissues that have not been cultured in vitro.

[0341] For example, the migratory body described in the present application can be produced from cells derived from an organism. For example, the organism can include a mammal. For example, the organism can include a human, a monkey, a mouse, a rat, a dog, a rabbit, a chicken and / or an insect. For example, the production cell of the migratory body described in the present application includes and is not limited to a tissue cell. For example, the migratory body described in the present application can be produced from a tissue cell extracted from an organism. For example, the migratory body described in the present application can be produced from a tissue cell extracted from an organism, for example, the migratory body described in the present application can be produced from a tissue cell cultured in vitro after extraction from an organism.

[0342] In the present application, the migrasomes may be generated from tumor cells.

[0343] For example, the tumor cells described in the present application may be derived from a subject sample. For example, the tumor cells described in the present application may include primary or limited passage tumor cells, tumor stromal cells, and / or tumor organoids derived from individual tissues. For example, the tumor cells described in the present application may include primary tumors, metastatic tumors, and / or cancer cells. For example, the tumor cells described in the present application may include tumor tissue or cancer cells extracted from an individual. For example, the tumor cells described in the present application may include tumor tissue or cancer cells extracted from an individual without culture and / or cultured in vitro after extraction. For example, extraction may include harvesting tumor tissue or cancer cells from an individual's tissue biopsy. For example, extraction may include harvesting tumor tissue or cancer cells from a biopsy of a tumor or cancer site of an individual. For example, extraction may include harvesting tumor tissue or cancer cells from a biopsy of an individual's circulating tumor or cancer cell. For example, the biopsy can include a bone biopsy, a bone marrow biopsy, a breast biopsy, a gastrointestinal biopsy, a lung biopsy, a liver biopsy, a prostate biopsy, a nervous system biopsy, a urogenital biopsy, a lymph node biopsy, a muscle biopsy, a skin biopsy, a blood biopsy, a body fluid biopsy, a heart biopsy, an endometrial biopsy, an open biopsy, a sentinel lymph node biopsy, any derivatives thereof, or any combination thereof. For example, the biopsy can include a fine needle aspiration biopsy, a core needle biopsy, a vacuum-assisted biopsy, an excisional biopsy, a shaving biopsy, a punch biopsy, an endoscopic biopsy, a laparoscopic biopsy, a bone marrow aspiration biopsy, a liquid biopsy, any derivatives thereof, or any combination thereof. For example, the biopsy can include an incisional biopsy or an excisional biopsy.

[0344] For example, the tumor cells described herein may include tumors or cancer cells extracted from an individual and without any in vitro culture after extraction. For example, the migratory bodies described herein are produced from the single cell suspension prepared by the tissue. For example, the migratory bodies described herein may include migratory bodies produced by any cell type described herein.

[0345] For example, the tumor cells described herein may include, but are not limited to, colorectal cancer cells and / or breast cancer cells.

[0346] For example, the tumor cells described herein may include, but are not limited to, mouse tumor cell lines or primary tumor cells. For example, the tumor cells described herein may include, but are not limited to, mouse fibrosarcoma MCA-205 cells and / or mouse breast cancer 4T1 cells.

[0347] For example, the tumor cells described herein may include human tumor cell lines, primary tumor cells and / or tumor organoids.

[0348] For example, when the migratory body described in the present application is produced from tumor cells, the migratory body can have an anti-tumor effect. For example, the migratory body can have one or more of the following: the reduction of the number of tumor cells, the reduction of tumor cell proliferation, the reduction of tumor cell survival, the reduction of tumor volume, the reduction of the number of metastases, the increase of life expectancy or the improvement of various physiological symptoms related to cancerous conditions. For example, the anti-tumor can include tumor prevention or tumor prevention. For example, the anti-tumor can include preventing the transfer and / or recurrence of tumor cells and / or reducing the recurrence rate of tumors.

[0349] The function and / or effect of the translocons described herein can be personalized.

[0350] The function and / or effect of the migrator described in the present application can have a specific corresponding relationship with the cell from which it is produced. For example, the cell from which the migrator is produced has a specific corresponding relationship with the type of disease to be treated. For example, the tumor cell from which the migrator is produced has a specific corresponding relationship with the type of tumor to be treated. For example, the migrator is produced from rectal cancer cells, and the migrator has a specific function and / or effect against rectal cancer. For example, the migrator is produced from breast cancer cells, and the migrator has a specific function and / or effect against breast cancer.

[0351] The function and / or effect of the migrator described in the present application can have a specific corresponding relationship with the source object of the cell from which it is produced. For example, the migrator can be produced from the cells of a specific object, and the migrator has a specific function and / or effect on the specific object. For example, the migrator can be produced from the tumor cells of a specific object, and the migrator has a specific anti-tumor function and / or effect on the tumor of the object.

[0352] The migratory body described in the present application can be produced from cells that are not directly genetically modified by engineering. For example, the migratory body described in the present application can be produced from cells that do not express exogenous antigens. The migratory body described in the present application can be produced from cells that are not engineered. For example, the migratory body described in the present application can be produced from cells that are not modified by gene expression. For example, the migratory body described in the present application can be produced from cells whose genomes are not modified and / or modified. For example, the migratory body described in the present application can be produced from cells that have not been transformed and / or modified in the form of vectors for gene expression. For example, the migratory body described in the present application can be produced from cells that do not express exogenous nucleic acid sequences. The migratory body described in the present application can also be produced from cells that are directly genetically modified by engineering. For example, the migratory body described in the present application can be produced from cells that express exogenous antigens. The migratory body described in the present application can be produced from cells that are not engineered. For example, the migratory body described in the present application can also be produced from cells that are engineered. For example, the migratory body described in the present application can be produced from cells whose genomes are transformed and / or modified. For example, the migratory body described in the present application can be produced from cells that have been transformed and / or modified in the form of vectors for gene expression. For example, the migrasomes described herein can be generated from cells expressing exogenous nucleic acid sequences.

[0353] The migratory body described in the present application may include a migratory body generated from a subject sample. The subject sample described in the present application may include a cell from which the migratory body described in the present application is generated. For example, the subject sample includes a cell of a subject, and the migratory body is generated from a cell of the subject. The cell from which the migratory body described in the present application is generated can be derived from a subject sample. For example, the migratory body is generated from a cell, and the cell can be derived from a subject sample.

[0354] Method for preparing migratory bodies

[0355] The migrating bodies described in the present application may include migrating bodies produced in vitro or ex vivo.

[0356] In another aspect, the present application provides a migrating body, wherein the migrating body comprises a migrating body prepared by a method for engineering migrating bodies.

[0357] In another aspect, the present application provides a method for preparing the migration body described in the present application.

[0358] For example, the method described in the present application may include causing the cell to produce a relative displacement and then produce a migrator derived from the cell. For example, the relative displacement of the present application may refer to the displacement of the cell center relative to the environment (e.g., the attached surface), or when the cell center is stationary, its membrane surface is still relative to the surrounding microenvironment (such as an attached solid surface, or a liquid phase in the microenvironment) or relative to the cell center (such as expansion, deformation from flat to bulge). For example, the generation and / or degree of the relative displacement can be intervened by physical and / or chemical and / or biological means.

[0359] For example, the method of the present application may further include isolating the migratory bodies produced by the cells.

[0360] For example, the method of the present application may include subjecting the cell to low osmotic pressure treatment, destroying the cytoskeleton of the cell, inhibiting the cell volume regulation function of the cell, causing the cell to detach from its adhesion surface, and / or causing relative displacement between the cell membrane and its adhesion surface, and may include increasing the amount and / or function of tetraspanin protein, its functional fragment and / or functional variant in the cell.

[0361] For example, in the method of the present application, it may include destroying the cytoskeleton of the cell, inhibiting the cell volume regulation function of the cell, detaching the cell from its adhesion surface, and / or causing a relative displacement between the cell membrane of the cell and its adhesion surface, and may include increasing the quantity and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell. For example, in the method of the present application, it may include treating the cell with low osmotic pressure, inhibiting the cell volume regulation function of the cell, detaching the cell from its adhesion surface, and / or causing a relative displacement between the cell membrane of the cell and its adhesion surface, and may include increasing the quantity and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell. For example, in the method of the present application, it may include treating the cell with low osmotic pressure, destroying the cytoskeleton of the cell, detaching the cell from its adhesion surface, and / or causing a relative displacement between the cell membrane of the cell and its adhesion surface, and may include increasing the quantity and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell. For example, in the method of the present application, it may include treating the cell with low osmotic pressure, destroying the cytoskeleton of the cell, inhibiting the cell volume regulation function of the cell, and / or causing relative displacement between the cell membrane of the cell and its adhesion surface, and may include increasing the amount and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell. For example, in the method of the present application, it may include treating the cell with low osmotic pressure, destroying the cytoskeleton of the cell, inhibiting the cell volume regulation function of the cell, and / or causing the cell to detach from its adhesion surface, and may include increasing the amount and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell.

[0362] For example, in the method of the present application, it may include inhibiting the cell volume regulation function of the cell, causing the cell to detach from its adhesion surface, and / or causing a relative displacement between the cell membrane of the cell and its adhesion surface, and may include increasing the amount and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell. For example, in the method of the present application, it may include treating the cell with low osmotic pressure, causing the cell to detach from its adhesion surface, and / or causing a relative displacement between the cell membrane of the cell and its adhesion surface, and may include increasing the amount and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell. For example, in the method of the present application, it may include treating the cell with low osmotic pressure, destroying the cytoskeleton of the cell, and / or inhibiting the cell volume regulation function of the cell, and may include increasing the amount and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell.

[0363] For example, in the method of the present application, it may include treating the cell with low osmotic pressure and / or causing a relative displacement between the cell membrane and its adhesion surface, and may include increasing the amount and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell. For example, in the method of the present application, it may include destroying the cytoskeleton of the cell and / or causing a relative displacement between the cell membrane and its adhesion surface, and may include increasing the amount and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell. For example, in the method of the present application, it may include inhibiting the cell volume regulation function of the cell and / or causing a relative displacement between the cell membrane and its adhesion surface, and may include increasing the amount and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell.

[0364] For example, the method of the present application may include subjecting the cells to a low osmotic pressure treatment.

[0365] For example, in the method of the present application, the low osmotic pressure treatment may include placing the cells in a low osmotic buffer solution.

[0366] For example, in the method of the present application, the low osmotic pressure treatment may include placing the cells in a buffer solution, and reducing the osmotic pressure of the buffer solution to a low osmotic pressure buffer.

[0367] For example, in the method of the present application, the reduction may include linear reduction and / or step-wise reduction.

[0368] For example, in the method of the present application, the osmotic pressure of the hypotonic buffer solution may be lower than about 305 mOsmol / L. For example, the osmotic pressure of the hypotonic buffer solution can be less than about 305 mOsmol / L, less than about 300 mOsmol / L, less than about 270 mOsmol / L, less than about 250 mOsmol / L, less than about 200 mOsmol / L, less than about 150 mOsmol / L, less than about 100 mOsmol / L, less than about 90 mOsmol / L, less than about 80 mOsmol / L, less than about 70 mOsmol / L, less than about 60 mOsmol / L, less than about 50 mOsmol / L, less than about 40 mOsmol / L, less than about 30 mOsmol / L, less than about 20 mOsmol / L, less than about 15 mOsmol / L, less than about 10 mOsmol / L, less than about 5 mOsmol / L, or less than about 2 mOsmol / L.

[0369] For example, in the method of the present application, the osmotic pressure of the hypotonic buffer solution can be about 10mOsmol / L to about 274.5mOsmol / L. For example, in the method of the present application, the osmotic pressure of the hypotonic buffer solution can be about 10mOsmol / L to about 274.5mOsmol / L.For example, the osmotic pressure of the hypotonic buffer solution can be about 10 mOsmol / L to about 300 mOsmol / L, about 20 mOsmol / L to about 300 mOsmol / L, about 30 mOsmol / L to about 300 mOsmol / L, about 50 mOsmol / L to about 300 mOsmol / L, about 70 mOsmol / L to about 300 mOsmol / L, about 100 mOsmol / L to about 300 mOsmol / L, about 150 mOsmol / L to about 300 mOsmol / L, about 200 mOsmol / L to about 300 mOsmol / L, about 250 mOsmol / L to about 300 mOsmol / L, about 10 mOsmol / L to about 250mOsmol / L, about 20mOsmol / L to about 250mOsmol / L, about 30mOsmol / L to about 250mOsmol / L, about 50mOsmol / L to about 250mOsmol / L, about 70mOsmol / L to about 250mOsmol / L, about 100mOsmol / L to about 250mOsmol / L, about 150mOsmol / L to about 250mOsmol / L, about 200mOsmol / L to about 250mOsmol / L, about 10mOsmol / L to about 200mOsmol / L, about 20mOsmol / L to about 200mOsmol / L, about 30mOsmol / L to about 200mOsmol / L, about 50mOsmol / L to about 200mOsmol / L, about 70mOsmol / L to about 200mOsmol / L, about 100mOsmol / L to about 200mOsmol / L, about 150mOsmol / L to about 200mOsmol / L, about 10mOsmol / L to about 150mOsmol / L, about 20mOsmol / L to about 150mOsmol / L, about 30mOsmol / L to about 150mOsmol / L, about 50mOsmol / L to about 150mOsmol / L, about 70mOsmol / L to about 150mOsmol / L In some embodiments, the present invention relates to a method for producing a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: a sodium-ion battery comprising: aThe hypotonic pressure treatment comprises placing the cells in a buffer solution and reducing the osmotic pressure of the buffer solution to a hypotonic buffer solution.

[0370] For example, in the method of the present application, it may include destroying the cytoskeleton of the cell.

[0371] For example, in the method of the present application, wherein the cytoskeleton of the cell is destroyed, it can include contacting the cell with a cytoskeleton-destroying agent. For example, in the method of the present application, wherein the cytoskeleton-destroying agent can include a microfilament and / or microtubule depolymerizing agent. For example, in the method of the present application, wherein the cytoskeleton-destroying agent can include Latrunculin A, Latrunculin B, cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D and / or cytochalasin E.

[0372] For example, in the method of the present application, it may include inhibiting the cell volume regulation function of the cell.

[0373] For example, in the method of the present application, wherein the cell volume regulation function of the cell is inhibited, the amount and / or function of the volume regulation protein in the cell may be decreased. For example, relative to unmodified cells, the amount and / or function of the volume regulation protein in the cell in which the cell volume regulation function is inhibited by the present application is decreased by about 5%, by about 10%, by about 20%, by about 50%, or by about 100%.

[0374] For example, in the method of the present application, the volume regulating protein may include a volume regulating ion channel and / or a transporter. For example, in the method of the present application, the volume regulating ion channel may include a volume regulating anion channel VRAC and / or a volume regulating cation channel VRCC. For example, in the method of the present application, the volume regulating anion channel VRAC may include SWELL1 or a functionally active fragment thereof. For example, in the method of the present application, the volume regulating cation channel VRCC may include TRPV4, TRPM3 and / or a functionally active fragment thereof.

[0375] For example, in the method of the present application, the transporter may include a co-transporter. For example, in the method of the present application, the co-transporter may include KCC1, KCC3 and / or KCC4.

[0376] For example, in the method of the present application, wherein inhibiting the cell volume regulation function of the cell may include placing the cell in a buffer solution with a weakened volume regulation ability. For example, in the method of the present application, wherein the buffer may contain increased cations. For example, in the method of the present application, wherein the cation may include K+, Na+, Cs+, Li+, Ca2+, Mg2+, Ba2+, Mn2+, Fe2+, Ni2+, Zn2+, Al3+, Fe3+, CH3NH3+, C2H5NH3+, (CH3)2NH2+, (C2H5)2NH2+, (C2H5)3N+, ammonium ions and / or choline ions.

[0377] For example, in the method of the present application, the buffer may contain increased anions. For example, in the method of the present application, the anions may include Br-, Cl-, I-, F-, OH-, HCO3-, H2PO4-, NO2-, NO3-, CN-, HPO42-, CO32-, SO42- and / or PO43-.

[0378] For example, in the method of the present application, the method may include detaching the cell from its adhesion surface.

[0379] For example, in the method of the present application, the method may include causing a relative displacement between the cell membrane of the cell and its adhesion surface.

[0380] For example, in the method of the present application, it may also include increasing the amount and / or function of the tetraspanin protein, its functional fragment and / or functional variant in the cell. For example, in the method of the present application, it may include causing the cell to overexpress the tetraspanin protein, its functional fragment and / or functional variant. For example, in the method of the present application, the tetraspanin protein may be selected from the group consisting of: Tspan1, Tspan2, Tspan3, Tspan4, Tspan5, Tspan6, Tspan7, Tspan8, Tspan9, Tspan10, Tspan11, Tspan12, Tspan13, Tspan14, Tspan15, Tspan16, Tspan17, Tspan18, Tspan19, Tspan20, Tspan21, Tspan22, Tspan23, Tspan24, Tspan25, Tspan26, Tspan27, Tspan28, Tspan29, Tspan30, Tspan31, Tspan32, Tspan33, Tspan34, Tspan35, Tspan36, Tspan37, Tspan38, Tspan39, Tspan40, Tspan41 Tspan20 (UPK1B), Tspan21 (UPK1A), Tspan22 (PRPH2), Tspan23 (ROM1), Tspan24 (CD151), Tspan25 (CD53), Tspan26 (CD37), Tspan27 (CD82), Tspan28 (CD81), Tspan29 (CD9), Tspan30 (CD63), Tspan31, Tspan32 and Tspan33.

[0381] For example, in the method of the present application, the method may further include reducing the size of the migration body.

[0382] For example, in the method of the present application, reducing the size of the migration body may include using a filter, squeezing with a squeezer, and / or treating the migration body with an ultrasonicator.

[0383] For example, in the method of the present application, the pore size of the filter or squeezer can be about 30nm to about 10000nm. For example, the pore size of the filter or squeezer can be about 30nm to about 100nm, about 30nm to about 1000nm, about 30nm to about 1000nm, about 50nm to about 100nm, about 50nm to about 1000nm, about 50nm to about 1000nm, about 100nm to about 1000nm, about 100nm to about 1000nm, or about 1000nm to about 10000nm.

[0384] Migration

[0385] The detached migratoria is an extracellular vesicle that has many differences from known extracellular vesicles. For example, the differences between migrasomes and exosomes: 1) The structures of the two are different: migrasomes are attached to contractile filaments before being released and present a structure of small vesicles contained in large vesicles; while exosomes do not have this structure; 2) The sizes of the two are different: the diameter of exosomes is about 50-150nm, while the diameter of migrasomes is about 0.5-3μm; 3) The protein composition of the two is significantly different: only 27% of the protein composition is the same between migrasomes and exosomes, for example, NDST1 (bifunctional heparan sulfate N-deacetylase / N-sulfotransferase 1), PIGK (phosphatidylinositol glycan anchor biosynthesis class K), CPQ (carboxypeptidase Q) and EOGT (EGF domain-specific O-linked N-acetylglucosamine transferase) are enriched in migrasomes but not in exosomes (Zhao X, Lei Y, Zheng J, Peng J, Li Y, Yu L, Chen Y. Identification of markers for migrasome detection. Cell Discov. 2019 May 21;5:27); 4) The two are regulated by different genetic pathways and have completely different biogenesis processes: exosomes are first produced as vesicles of multivesicular bodies (MVBs), and exosomes are released when MVBs fuse with the plasma membrane; while migrasomes are formed by the assembly of large domains on the plasma membrane (Huang Y, Zucker B, Zhang S, Elias S, Zhu Y, Chen H, Ding T, Li Y, Sun Y, Lou J, Kozlov MM*, Yu L*. Migrasome formation is mediated by assembly of micron-scale tetraspanin macrodomains. Nat Cell Biol. 2019 Aug;21(8):991-1002).

[0386] The migrator described in the present application may have the characteristics of the migrator. For example, the migrator described in the present application may be detected and / or analyzed by the characteristics of the migrator. For example, the migrator described in the present application may be detected and / or analyzed by one or more of the following methods: using confocal microscopy, using electron microscopy, total protein quantification, immunoblotting, mass spectrometry, ELISA, Luminex or MSD multiple protein quantification, flow cytometry, microfluidic separation, sequencing, and / or using a particle size analyzer.

[0387] For example, the function and / or effect of the translocon described herein may be related to its characteristics as a translocon.

[0388] For example, the cholesterol concentration and total protein concentration ratio of the migrator described in the present application can be higher than that of the cell from which it is derived. For example, the cholesterol concentration and total protein concentration ratio of the migrator described in the present application can be higher than that of the cell from which it is derived by at least 50%. For example, when using the same total protein amount sample for comparison, the cholesterol concentration of the migrator described in the present application can be higher than that of the cell from which it is derived.

[0389] For example, the sphingomyelin concentration of the migrator described in the present application can be higher than that of the cell from which it is derived. For example, the phospholipid concentration of the migrator described in the present application can be at least 50% higher than that of the cell from which it is derived. For example, when using the same total protein amount sample for comparison, the sphingomyelin to phosphatidylglycerol ratio of the migrator described in the present application can be higher than that of the cell from which it is derived.

[0390] For example, the migrator described herein may have a chemokine and / or its receptor.

[0391] For example, the migratory bodies described herein may have adhesion factors.

[0392] For example, the size of the migration body described in the present application can be about 50nm to about 8000nm. For example, the size of the migration body described in the present application can be about 50nm to about 8000nm. For example, the size of the migration body described in the present application can be about 50nm to about 100nm, about 50nm to about 1000nm, about 50nm to about 1000nm, about 100nm to about 1000nm, about 100nm to about 10000nm, or about 1000nm to about 10000nm.

[0393] For example, the migrating body described in the present application may include contractile filaments.

[0394] For example, the membrane of the migration body described in the present application may be enriched with sodium / potassium ATPase and / or its functional fragments. For example, the membrane of the migration body described in the present application may be enriched with integrin and / or its functional fragments. For example, the membrane of the migration body described in the present application may be enriched with tetraspanin protein, its functional variant and / or its functional fragment. For example, the membrane of the migration body described in the present application may be enriched with cholesterol. For example, enrichment may refer to comparison with other parts of the cell membrane of the corresponding cell, or compared with the situation on the corresponding cell membrane before the migration body is produced. For example, enrichment means that the density of the molecules or substances on the migration body of the present application is higher than the density of the corresponding molecules or substances on the cell membrane that produces these migration bodies.

[0395] For example, the migrator described in the present application may be enriched with membrane microdomains. For example, membrane microdomains refer to microdomains of cell membranes based on sphingolipids and cholesterol (Ch), including lipid rafts, tetraspanin-enriched microdomains (TEM), and the like.

[0396] Engineered Migratoria

[0397] The migratory bodies described in the present application may include engineered migratory bodies.

[0398] For example, the migratory body described in the present application, compared with the natural migratory body produced by the same cell, the content of the migratory body can be at least partially reduced or missing. For example, taking the engineered migratory body produced by NRK cells as an example, compared with the natural migratory body, there are 4000 or more migratory bodies with protein deletion, and the natural migratory body has about 1350 proteins (i.e., extra proteins) that are not present in the natural migratory body, such as AMP3, Myh4, Gorasp2, Asz1, Lats2, Scn2b, Pacsin1, Alb. For example, "natural migratory body" can refer to the migratory body produced by spontaneous migration without changing the external culture conditions (such as hypotonicity, temperature, etc.) of the cell; and "engineered migratory body" can refer to the migratory body produced after the cell is induced to have relative displacement by external stimulation.

[0399] For example, the at least partially reduced contents described herein may include intraluminal vesicles. For example, the interior of the migrator described herein has fewer intraluminal vesicles. For example, the intraluminal vesicles may refer to vesicles having a phospholipid bilayer structure in the outer membrane structure.

[0400] cell

[0401] In another aspect, the present application provides a cell capable of producing the migratoria described in the present application.

[0402] For example, the cell may include the migrator described in the present application produced by any of the migrator preparation methods described in the present application. For example, the cell described in the present application may be a cell cultured on a wall. For example, the cell described in the present application may include being present in a single cell suspension state. For example, the cell described in the present application may include being present in a state of adherent growth.

[0403] For example, the cell may have certain characteristics that enable it to produce the migrasome described herein.

[0404] Vaccine composition

[0405] In another aspect, the present application provides a vaccine composition, comprising the migrator described in the present application.

[0406] For example, the vaccine composition may include other immunologically active components. For example, the vaccine composition may include immunologically active components other than the migrator described herein. For example, the vaccine composition may be a combination vaccine or a multivalent vaccine. For example, the vaccine composition may stimulate a host to produce an immune response against multiple pathogens or tumors, and the vaccine composition is produced using multiple immunogens and administered in a single dosage form.

[0407] For example, the vaccine composition may include an immunoadjuvant. For example, the immunoadjuvant may include all substances that can accelerate, prolong or enhance the quality of the specific immune response to the antigen. For example, the immunoadjuvant does not show obvious toxicological effects in vivo. For example, the immunoadjuvant may include and is not limited to polyinosinic acid cytosine nucleotide (Poly I: C).

[0408] For example, the vaccine composition may include a pharmaceutically acceptable carrier.

[0409] The vaccine compositions described herein can be personalized.

[0410] For example, the vaccine composition can be a prophylactic or preventive composition. For example, the vaccine composition can be a therapeutic or therapeutic pharmaceutical composition.

[0411] Pharmaceutical composition

[0412] On the other hand, the present application provides a pharmaceutical composition comprising the migrator described in the present application and / or the vaccine composition described in the present application.

[0413] For example, the pharmaceutical composition described herein may include other therapeutic agents. For example, the pharmaceutical composition may include therapeutic agents other than the migrator described herein. For example, the therapeutic agent may include any agent used to treat a disease. For example, the therapeutic agent may include an immunomodulator. For example, the immunomodulator includes an inhibitor of an immune checkpoint or an inhibitor of a binding ligand of an immune checkpoint. For example, the immunomodulator may include an antibody or its antigen binding protein or binding fragment or a receptor / ligand and / or a compound or any combination thereof.

[0414] For example, the pharmaceutical compositions described herein may include a pharmaceutically acceptable carrier.

[0415] The pharmaceutical compositions described herein can be personalized.

[0416] For example, the pharmaceutical composition can be a prophylactic or preventive composition.For example, the pharmaceutical composition can be a therapeutic or therapeutic pharmaceutical composition.

[0417] The vaccine composition and pharmaceutical composition of the present application can be used by multiple approaches, including but not limited to oral, intravenous, intramuscular, intraarterial, intracranial, intramedullary, intrathecal, intraventricular, transdermal, percutaneous, subcutaneous, intraperitoneal, intranasal, enteral, local, sublingual, intravaginal, intrarectal, intravesical, intralesional (e.g., intratumoral), lymph node / ductal approaches. The pharmaceutical composition of the present application can also be used with a needleless syringe. Usually, the therapeutic composition can be prepared into an injectable as a liquid solution or suspension. Solid forms suitable for dissolving or being suspended in a liquid vehicle before injection can also be prepared. The vaccine composition and / or pharmaceutical composition comprising the therapeutic dose of the migrator of the present application do not show obvious toxicological effects in vivo.

[0418] Therapeutic Uses / Methods

[0419] On the other hand, the present application also provides a use of the migrator described in the present application, the vaccine composition described in the present application and / or the pharmaceutical composition described in the present application in the preparation of drugs for preventing and / or treating diseases.

[0420] On the other hand, the present application also provides a use of the migrator described in the present application, the vaccine composition described in the present application and / or the pharmaceutical composition described in the present application in preventing and / or treating a disease.

[0421] On the other hand, the present application also provides a method for preventing and / or treating a disease, the method comprising administering a pharmaceutically effective amount of the migration body described in the present application, the vaccine composition described in the present application and / or the pharmaceutical composition described in the present application to a subject in need.

[0422] On the other hand, the present application also provides a method for inducing or regulating an immune response in a subject in need thereof, the method comprising administering to the subject a pharmaceutically effective amount of the migration body described in the present application, the vaccine composition described in the present application and / or the pharmaceutical composition described in the present application.

[0423] For example, the disease described herein may include, but is not limited to, tumors. For example, the disease described herein may include, but is not limited to, malignant tumors and / or cancer. In some embodiments, the tumor is characterized by infiltration of leukocytes (T cells, B cells, macrophages, dendritic cells, monocytes, neutrophils) to the tumor microenvironment, or so-called "hot tumors" or "inflammatory tumors". In some embodiments, the tumor is characterized by infiltration of leukocytes to the tumor microenvironment at low or undetectable levels, or so-called "cold tumors" or "non-inflammatory tumors".

[0424] In some embodiments, the disease treated can include, but is not limited to, metastatic malignancies, unresectable refractory malignancies (eg, malignancies that are resistant or resistant to previous therapy), and / or recurrent malignancies.

[0425] For example, the prevention and / or treatment of tumors described herein may include a reduction in the number of tumor cells, a reduction in tumor cell proliferation, a reduction in tumor cell survival, a reduction in tumor volume, a decrease in the number of metastases, an increase in life expectancy, or an improvement in various physiological symptoms associated with cancerous conditions.

[0426] In some embodiments, the use of the migratory body described in the present application, the vaccine composition described in the present application and / or the pharmaceutical composition of the present application can suppress and / or reduce the tumor growth of the subject. For example, tumor growth (e.g., tumor volume or weight) is reduced by at least about 5%, less than about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or about 100% compared with a reference (e.g., before the application and / or without the vaccine composition and / or the pharmaceutical composition of the present application).

[0427] In some embodiments, the use of the migrator described in the present application, the vaccine composition described in the present application and / or the pharmaceutical composition of the present application can prevent tumor metastasis in the subject. For example, the migrator described in the present application, the vaccine composition described in the present application and / or the pharmaceutical composition of the present application of a therapeutically effective amount is applied to the subject, and one or more tumors in one part of the subject can be prevented from promoting one or more tumor growth in another part of the subject. In some embodiments, a composition is applied intratumorally in a first tumor in a part, and the composition applied in the first tumor prevents one or more tumor metastasis in a second part.

[0428] In some embodiments, the administration of the migratory bodies described herein, the vaccine compositions described herein, and / or the pharmaceutical compositions of the present application can prevent tumors. In some embodiments, the administration of the migratory bodies described herein, the vaccine compositions described herein, and / or the pharmaceutical compositions of the present application can prevent the initial occurrence of tumors. For example, the subject has not been diagnosed with a tumor, and the administration of the migratory bodies described herein, the vaccine compositions described herein, and / or the pharmaceutical compositions of the present application can prevent tumor growth in the subject. In some embodiments, the administration of the migratory bodies described herein, the vaccine compositions described herein, and / or the pharmaceutical compositions of the present application can prevent the recurrence of tumors. For example, the subject has been confirmed to have a tumor and has received or is receiving tumor treatment, and the administration of the migratory bodies described herein, the vaccine compositions described herein, and / or the pharmaceutical compositions of the present application can prevent the recurrence and / or metastasis of tumors in the subject.

[0429] In some embodiments, the administration of the migrator described herein, the vaccine composition described herein, and / or the pharmaceutical composition of the present application can convert a "cold tumor" into a "hot tumor". For example, the migrator described herein, the vaccine composition described herein, and / or the pharmaceutical composition of the present application are administered in an amount and duration sufficient to convert a "cold tumor" into a "hot tumor", that is, the administration can result in infiltration of immune cells (such as T cells, B cells, NK cells, antigen presenting cells) into the tumor microenvironment.

[0430] The treatment methods and / or therapeutic uses described herein may include combination with one or more other treatment methods.

[0431] For example, the disease described in the present application may include a tumor, and the other treatment methods may include one or more anti-tumor treatment methods. For example, the one or more anti-tumor treatments are selected from the group consisting of chemotherapy, radiotherapy, immunotherapy, or a combination thereof. For example, the immunotherapy includes the administration of an immunomodulator. For example, the immunomodulator includes an inhibitor of an immune checkpoint or an inhibitor of a binding ligand of an immune checkpoint. For example, the immune checkpoint may include cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 and its ligand 1, ligand 2 (PD-1, PD-L1, PD-L2), HPK1 (Hematopoietic Progenitor Kinase 1, hematopoietic progenitor cell kinase 1), OX-40 (also known as CD134, TNFRSF4), OX-40L (OX-40 ligand,), lymphocyte activation gene 3 (LAG-3), T cell immunoglobulin mucin-containing protein 3 (TIM-3), B lymphocyte and T lymphocyte attenuator (BTLA) and its ligand HVEM, T cell immune receptor with Ig and ITIM domains (TIGIT), V domain Ig inhibitor of T cell activation (VISTA), adenosine A2a receptor (A2aR), killer cell immunoglobulin-like receptor (KIR), indoleamine 2,3-dioxygenase (IDO), CD39, CD73, CD47, CD24, CD161, sialic acid binding immunoglobulin-like lectin (Siglec-15) or any combination thereof. For example, the immunomodulator includes an agonist of an immune co-stimulatory molecule or its binding ligand. For example, the costimulatory molecules may include and are not limited to one or more or any combination of B7 family / CD28, tumor necrosis factor (TNF)-TNF receptor superfamily and / or immunoglobulin superfamily members. For example, the costimulatory molecules and ligands include CD26, CD27 / CD70, CD28 / CD80 / CD86, CD40 / CD40L, 4-1BB (CD137) / 4-1BBL, OX40 (CD134) / OX40L, GITR / GITRL, HVEM (CD270) / LIGHT or LTα, TNF / TNFRs and inducible T cell costimulator (ICOS) or any combination thereof.

[0432] For example, the immunomodulator can include an antibody or its antigen binding fragment, a receptor and / or a ligand and / or a compound or any combination thereof. In some embodiments, the antibody or its antigen binding fragment is one or more complete antibodies, polyclonal antibodies, monoclonal antibodies and recombinant antibodies, fragments thereof, and also includes single-chain antibodies, humanized antibodies, mouse antibodies, chimeric antibodies, mouse-human antibodies, mouse-primate antibodies, primate-human monoclonal antibodies, anti-idiotypic antibodies, antibody fragments, such as, scFv, (scFv) 2, Fab, Fab' and F(ab') 2, F(ab1) 2, Fv, dAb and Fd fragments, double antibodies and antibody-related polypeptides. The term antibody includes bispecific antibodies and multispecific antibodies, as long as they show desired biological activity or function.

[0433] Without intending to be bound by any theory, the following examples are merely intended to illustrate the fusion protein, preparation method and use of the present application, and are not intended to limit the scope of the present invention.

[0434] Example

[0435] The present application is further described by the following specific examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods in the following examples without specifying specific conditions are carried out according to the conventional conditions in the art, for example, Sambrook and Russeii et al., Molecular Cloning: A Laboratory Manual (3rd Edition) (2001), the conditions described in CSHL Press, or according to the conditions recommended by the manufacturer. Unless otherwise stated, the experimental materials and reagents used in the following examples are all commercially available.

[0436] Reagents

[0437] ddH2O (Solarbio, Catalog No. F0020), KCl (Sigma, Catalog No. P5405-1KG), KH2PO4 (Sangon, Catalog No. A600445), Na2HPO4-7H2O (Sangon, Catalog No. A600487), BSA (Sigma, Catalog No. SRE0098-100G), Latrunculin A (Cayman, Catalog No. 10010630), human fibronectin (Sigma, Catalog No. F0895-5MG), PBS (Gibco, Catalog No. 8122166), RPMI 1640 (Gibco, catalog number C11875500BT), FBS (VivaCell, catalog number C04001-500), WGA-AF488 / AF594 / AF647 (Invitrogen, catalog number W7024, W11262, W32466), BCA kit (Invitrogen, catalog number 23227), Poly I:C (Invitrogen, catalog number tlrl-picw), tumor tissue digestion kit (Miltenyi, catalog number 130-095-929).

[0438] Preparation of 10x KDPBS (500 mL):

[0439] Components Content (g) Concentration (mM) KCl 52.4 1405.7 <![CDATA[KH2PO4]]> 1 14.7 <![CDATA[Na2HPO4-7H2O]]> 10.8 80.6 <![CDATA[ddH2O]]> Up to 500mL

[0440] Preparation of 100x BSA (50 mL): Weigh 5 g of BSA, add ddH2O to 50 mL, and filter with a 0.45 μm filter membrane.

[0441] Example 1 Preparation of Migratory Bodies

[0442] 1.1 Obtaining single cell cultures

[0443] Remove the skin and connective tissue of the mouse MCA-205 (donated by Yu Li Laboratory, Tsinghua University) or 4T1 (ATCC, catalog number CRL-2539) tumor tissue blocks (<0.2g) from the sterile excised tissue and place them in a sterile 1.5mL centrifuge tube. Wash once with Hank's solution or PBS solution, add 1mL (tumor <0.2g) tumor tissue digestion solution (Miltenyi), and cut the tissue into small pieces (0.5-1mm) with surgical scissors. 3 ) and digest at 37°C for 40-60 minutes, shaking every 5 minutes to separate the cells. After digestion, filter with a 70μm cell sieve, centrifuge at 300x g for 5 minutes, and discard the supernatant. Add 5mL of Hank's solution, resuspend the cells, centrifuge again, and discard the supernatant. Add 1-2mL of culture medium depending on the number of cells, and count with a counting plate. Adjust the cell concentration to 5×10 5 / mL, transfer to a 25mL cell culture flask and culture at 37°C. After 48h of culture, discard the supernatant and non-adherent cells, add culture medium and continue culturing. When the cell density reaches 70-80%, it can be used for the production of migratoria or subculture.

[0444] 1.2 Preparation of engineered migrasomes

[0445] Prepare a mixture of 1×K-DPBS+Latrunculin A (final concentration 0.83μg / mL), marked as solution A. Take out the T175 culture flask with cells (density reaches 70%-80%) from the incubator and remove the supernatant. Wash the cells in each flask with PBS and discard the supernatant. Add 15mL of L-A solution, mix gently, and place in the incubator for disaggregation for 30 minutes. Add 5mL, 6.5mL, and 8.5mL of sterile water to the culture flask in sequence to reduce the osmotic pressure, and shake gently for 3-5 minutes. After discarding the supernatant, add 40% K-DPBS to wash the cells and discard the supernatant. Add K-DPBS containing BSA, pipette, and add the mixed supernatant to a 50mL centrifuge tube. Add an appropriate amount of K-DPBS containing BSA and pipette again.

[0446] Collect the supernatant and centrifuge at 4°C 300x g for 10 minutes. After centrifugation, collect the supernatant and filter it into a 50mL centrifuge tube with a 4μm filter and centrifuge it at 4°C 17000x g for 20-40 minutes. Resuspend the precipitate with 1mL PBS containing BSA and centrifuge it at 20000x g for 5-15 minutes. Then resuspend the precipitate in PBS or PBS containing BSA according to the purpose of use to obtain the prepared migrator.

[0447] Example 2 Detection of Migrant Vaccine

[0448] 2.1 Detection of produced migratoria vaccine using confocal microscopy

[0449] Figure 1 The migratoria tumor vaccine produced for MCA-205 cells has a morphology consistent with the characteristics of migratoria, which is a vesicle-like structure with uneven sizes, but the diameter of most vesicles is less than 10 microns.

[0450] Figure 2 The migrasome vaccine produced for 4T1 cells has a morphology consistent with the characteristics of migrasomes.

[0451] Figure 3 The migratoria tumor vaccine produced for cultured primary human skin squamous cell carcinoma cells (donated by the Cancer Hospital, Chinese Academy of Medical Sciences) has a morphology consistent with the characteristics of migratoria.

[0452] 2.2 Characterization of migratoria vaccine

[0453] Western Blot detection was performed based on the proteins enriched on the migration body, such as ITGAV, ITGA5, ITGB1, EOGT and PIGK, and histone3, Tsg101, Alix, GM130, Lamp2, etc. were added to eliminate contamination.

[0454] The results show that if Figure 4 As shown, compared with the cells from which they were produced, the migrasome tumor vaccine prepared using 4T1 cells and the migrasome tumor vaccine prepared using MCA-205 cells were both enriched in integrin α5 (ITGA5) and contained essentially no histone H3, which is consistent with the characteristics of migrasomes.

[0455] Example 3 Detection of the expression of human leukocyte antigen (HLA) molecules on migrasomes prepared from human primary tumor cells

[0456] In this example, flow cytometry was used to detect the expression of human leukocyte antigen (HLA) molecules on migrasomes prepared from human primary tumor cells.

[0457] Materials: APC anti-human HLA-A, B, C (Biolegend, Catalog No. 311409), WGA-AF488 (Wheat germagglutinin, Invitrogen, Catalog No. W7024), human primary tumor cell migratory bodies.

[0458] Detection method: Human primary tumor cells (donated by the Cancer Hospital of the Chinese Academy of Medical Sciences) were used to prepare migratory bodies, and the preparation method was the same as in Example 1. The prepared human primary tumor cell migratory bodies were dissolved in 40 μl PBS, which was called the human primary tumor cell migratory body stock solution. Take out 2 μl of the human primary tumor cell migratory body stock solution, add it to 400 μl PBS for dilution, add 2 μl APC anti-human HLA-A, B, C (Biolegend, catalog number 311409) to the dilution, incubate on ice for 20 minutes, and then add 1 μl WGA-AF488 (Invitrogen, catalog number W7024), and stain at room temperature for 10 minutes. WGA can stain oligosaccharides on the outer surface of the migratory body membrane. Thermo Attune NXT was used for flow cytometry detection, and the APC_HLA positive percentage was counted in the WGA-AF488-positive migratory bodies.

[0459] Test results are shown in Figure 5, it can be seen that for the migrasomes produced by WGA-AF488-positive human primary tumor cells, the expression of human leukocyte antigen (HLA) molecules on the migrasomes can be detected by flow cytometry. The R4 value in the figure below is the proportion of HLA-positive in WGA-AF488-positive migrasomes. It can be seen that the proportion of HLA-positive in WGA-AF488-positive migrasomes is 99.653%.

[0460] Example 4: Migration bodies carrying MHC-antigen polypeptide complexes

[0461] In this example, flow cytometry was used to detect whether the migrator carried the MHC-antigen polypeptide complex.

[0462] Experimental materials: H2Kb-IINFEKL-APC antibody (Invitrogen), MC38-OVA cell migratoria, wheat germ agglutinin (WGA. Invitrogen, catalog number W11262), Tspan4-GFP.

[0463] Detection method: MC38 cells overexpressing OVA antigen (donated by Yu Li Laboratory, Tsinghua University) were used to prepare MC38-OVA cell migratory bodies, and the preparation method was the same as in Example 1. Tspan4-GFP and WGA staining were used to mark the migratory bodies. Tspan4 is a protein marker enriched on the migratory body, and WGA can stain the oligosaccharides on the outer surface of the migratory body membrane. The MC38-OVA cell migratory body was stained with the H2Kb-IINFEKL-APC antibody that can recognize the MHCI-OVA antigen polypeptide complex, and flow cytometry analysis was performed after staining.

[0464] The staining results are shown in Figure 6 , it can be seen that there is a complex of MHC and OVA antigen polypeptide on the migrator, that is, there is a tumor antigen presented by MHC on the migrator.

[0465] Example 5 Migrasomes can activate and / or modulate immune responses

[0466] This example shows that the migrating body or migrating body vaccine described in the present application can effectively activate and / or regulate the immune response.

[0467] like Figure 7As shown, 12 female C57BL / 6N mice, 3 mice in each group, were intravenously injected with PBS twice on day 0 and day 7 in group 1; mice in group 2 were intravenously injected with MCA-205 migrator 2 μg / mouse twice; mice in group 3 were injected with Poly I:C 50 μg / mouse twice; mice in group 4 were injected with MCA-205 migrator 2 μg / mouse plus Poly I:C 50 μg / mouse twice. On day 14, spleen cells were obtained from mice, and cells were stimulated with adpgk mutant peptide (Mahesh Yadav et.al. Nature, volume 515, pages 572–576 (2014)), and then the number of IFNγ-positive cells was tested using IFNγ ELISPOT kit (Dakoway, Cat. No. 2210006).

[0468] The number of IFNγ-positive spots in mice injected with migrasome tumor vaccine in group 2 was significantly higher than that in PBS group in group 1. The number of IFNγ-positive spots in mice injected with migrasome tumor vaccine plus Poly I:C (group 4) was significantly higher than that in mice injected with Poly I:C alone (group 3).

[0469] Example 6 Migrasomes produced by tumor cells can be anti-tumor

[0470] This example shows that the migrasomes or migrasome vaccines produced by tumor cells described in the present application can be anti-tumor.

[0471] The efficacy of migratoria vaccines produced from 4T1 cells and MCA-205 cells was tested in mice.

[0472] 1. Immunization and tumor vaccination:

[0473] Mouse 4T1 breast cancer model

[0474] Thirty female BALB / c mice were weighed and randomly divided into groups according to their body weight;

[0475] · Intravenous injection of 100 μL PBS or 100 μL (2 μg) 4T1 migratory body tumor vaccine on the 21st and 17th day before tumor cell inoculation; subcutaneous injection of 1 mg / kg analgesic meloxicam injection 15 minutes before in situ inoculation on Day 0;

[0476] The mouse abdomen was shaved and anesthetized with isoflurane using an anesthesia machine. The mouse was fixed in supine position. The surgical site was disinfected with alcohol. A longitudinal incision of about 1 cm was made on the abdominal skin near the fourth mammary gland on the right side on the inoculation side. The skin was bluntly separated and the mammary fat pad was fixed from the inside of the skin with forceps. A 1 ml syringe was used to insert the needle horizontally for in situ inoculation.

[0477] Each mouse was inoculated with 50 μl of 4 × 10 6 / ml 4T1 cells;

[0478] The skin incision is closed with sutures or staples.

[0479] Mouse MCA-205 fibrosarcoma model

[0480] 28 female C57BL / 6N mice were weighed and randomly divided into groups according to body weight;

[0481] · Intravenous injection of 100 μL PBS or 100 μL (2 μg) of MCA-205 migratory body tumor vaccine on the 14th day and the 6th day before tumor cell inoculation, respectively;

[0482] On Day 0, each mouse was subcutaneously inoculated with 100 μl of 1×10 7 / ml MCA-205 cells.

[0483] 2. Clinical observation: Routine monitoring includes abnormalities in normal animal behavior, including the activity, food and water intake, eyes, fur and other abnormalities of experimental animals. Deaths or clinical symptoms observed during the experiment are recorded in the original data.

[0484] 3. Weigh your body twice a week and measure the tumor twice a week after tumor formation. The tumor volume calculation formula is: V (mm 3 )=a*b 2 / 2 (V-tumor volume, a is the long diameter of the tumor, b is the short diameter of the tumor);

[0485] 4. Tumor volume reaches 2000mm 3 Or when the weight of mice decreased by more than 20% or the mice were dying (symptoms such as inability to eat and lower body temperature), the mice were euthanized.

[0486] In vivo efficacy of migratoria tumor vaccines produced by 4T1 cells Figure 8 As shown, mice in group 1 were injected with PBS twice through the tail vein 21 days and 17 days before tumor inoculation. Group 2 was injected with PBS through the tail vein 21 days before tumor inoculation, and injected with a migrator tumor vaccine prepared with 4T1 cells once 17 days before tumor inoculation. Group 3 was vaccinated with a migrator tumor vaccine prepared with 4T1 cells twice 21 days before tumor inoculation and 17 days before tumor inoculation. Compared with group 1, the tumor volumes of mice in groups 2 and 3 were significantly reduced (P values ​​were calculated based on two-tailed T tests).

[0487] The effect of migratoria produced by MCA-205 cells on tumor vaccines is as follows Fig. 9As shown, mice in group 1 were injected with PBS twice via tail vein 14 days and 6 days before tumor inoculation. Group 2 was injected with migratoria tumor vaccine prepared with MCA-205 cells twice 14 days and 6 days before tumor inoculation. Compared with group 1, the tumor volume of mice in group 2 was significantly reduced (P value calculated by two-tailed T test).

[0488] Example 7 The vaccine effect of migrasomes is better than direct injection of tumor cell lysates

[0489] This example uses mouse experiments to verify that the immune effect of migrasomes prepared from tumor cells is better than that of tumor cell lysates.

[0490] Material:

[0491] G1: control group mice injected with PBS;

[0492] G2: mice immunized with migrasome tumor vaccine, where the migrasomes were prepared from B16F10 cells, and the preparation method was as described in Example 1;

[0493] G3: control group mice injected with cell lysate, wherein the cell lysate is B16F10 cell lysate.

[0494] Cell lysates were prepared by freezing and thawing B16F10 cells for 5 cycles, each cycle consisting of 10 minutes at -80 degrees Celsius and 10 minutes at 37 degrees Celsius.

[0495] Methods: Ten female C57BL / 6N mice were randomly divided into three groups. The mice were immunized on days 0 and 7: the first group (G1) was injected with phosphate buffered saline (PBS) twice as a control; the second group (G2) was injected with migrasome tumor vaccine twice to immunize the mice; the third group (G3) was injected with B16F10 cell lysate twice as a control. During the injection, both the migrasome vaccine and cell lysate were 2 μg / mouse / time. Then, the melanoma mouse model was established: each mouse was inoculated with 1x10 5 B16F10 tumor cells. After tumor formation, the tumor volume was measured twice a week, and the tumor volume was calculated as follows: V (mm 3 )=a×b 2 / 2 (V = tumor volume, a = tumor long diameter, b = tumor short diameter).

[0496] Tumor progression results Fig.10 As shown, it can be seen that in the B16F10 melanoma tumor model, the tumor growth rate of mice immunized with the migratoria tumor vaccine in G2 was significantly lower than that of the phosphate buffer control group (G2) and the cell lysate control group (G3). The vaccine effect of tumor cell migratoria is better than that of tumor cell lysate.

[0497] Example 8 Migratory bodies can produce long-lasting immunity as tumor vaccines

[0498] This example uses mouse experiments to verify that migrasomes can produce long-lasting immunity as tumor vaccines.

[0499] Materials: Female BALB / c mice, 4T1 cells, and 4T1 cell migratoria tumor vaccines.

[0500] Mice in group G1: mice immunized with 4T1 cell migratoria tumor vaccine and then inoculated with tumor cells again.

[0501] G2 group mice: mice that had not been vaccinated with the migratory tumor vaccine were inoculated with tumor cells.

[0502] Methods: BALB / c mice were vaccinated twice (on day 0 and day 7) with 4T1 cell migratoria tumor vaccine. 4T1 tumor cells were inoculated in the submammary fat pad on day 7 after the second vaccination. Each mouse was inoculated with approximately 1×10 5 The mice without tumors were selected as the first group (G1). The control mice that had not been immunized with tumor vaccines were selected as the second group (G2). The two groups of mice were inoculated with 1×10 5 4T1 tumor cells, tumor volume was measured after tumor formation. Tumors were measured twice a week after tumor formation, and the tumor volume was calculated as follows: V (mm 3 )=a×b 2 / 2 (V = tumor volume, a = tumor long diameter, b = tumor short diameter).

[0503] The experimental results are shown in Fig.11 As shown, it can be seen that the migratoria tumor vaccine can produce long-lasting immunity. The mice treated in the G1 group developed anti-tumor immunity, and after re-inoculation of tumor cells, the growth rate of the tumor was still slower than that of the control group.

Claims

1. A migrator comprising an antigen, wherein the migrator is produced from a cell that has not been directly genetically modified, wherein the migrator is produced from a tumor cell.

2. The migrator according to claim 1, wherein the tumor cells are selected from human tumor cell lines or human primary tumor cells.

3. The migrator according to claim 1 or 2, wherein the tumor cells are isolated from a sample from a cancer patient.

4. The migrating body according to claim 3, wherein the sample is a biopsy sample or a surgically removed tumor tissue sample.

5. The migrator according to claim 3 or 4, wherein the cancer is a solid tumor or a hematological tumor.

6. The migrator according to any one of claims 3-5, wherein the cancer is selected from breast cancer, fibrosarcoma, colorectal cancer, lung cancer, gastric cancer, liver cancer, kidney cancer, ovarian cancer, pancreatic cancer, bladder cancer, prostate cancer, skin cancer, head and neck cancer, brain cancer, leukemia, lymphoma, myeloma.

7. The migrator according to any one of claims 3-6, wherein the patient is a patient who has received previous treatment or a patient who has not received previous treatment.

8. The migrator according to claim 7, wherein the previous treatment is selected from surgery, chemotherapy, immunotherapy and radiotherapy.

9. The migrator according to claim 1, wherein the tumor cells are selected from the group consisting of human primary skin squamous cell carcinoma cells, mouse MC38 cells, mouse B16F10 melanoma tumor cells, mouse fibrosarcoma MCA-205 cells and mouse breast cancer 4T1 cells.

10. The migrating body of any one of claims 1-9, wherein the migrating body comprises a migrating body produced in vitro or ex vivo.

11. The migratory body according to any one of claims 1 to 10, wherein the migratory body is prepared by a method comprising the following steps: (a) treating cells with one or more of the following to induce the cells to produce migrasomes: (1) Hypoosmotic pressure treatment; (2) destroying the cytoskeleton of the cell; (3) inhibiting the cell volume regulation function of the cell; and (4) causing the cell to overexpress one or more proteins selected from members of the Tetraspanin family; and (b) isolating and / or purifying the migrating body. 12 . The migrator according to claim 11 , wherein the migrator is prepared by subjecting the cell to a hypoosmotic pressure treatment and destroying the cytoskeleton of the cell.

13. The migrator according to claim 11 or 12, wherein the hypoosmotic pressure treatment comprises placing the cells in a buffer solution and reducing the osmotic pressure of the buffer solution to 30.5-274.5 mOsmol, such as 30.5-150 mOsmol.

14. The migrator according to any one of claims 11-13, wherein said disrupting the cytoskeleton of said cell comprises contacting said cell with a cytoskeleton disrupting agent selected from the group consisting of Latrunculin A, Latrunculin B, cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D and cytochalasin E.

15. The migrator according to any one of claims 1 to 14, wherein the migrator contains molecules selected from the following: molecules involved in antigen presentation (e.g., MHC molecules and / or immune co-stimulatory molecules), chemokines and / or their receptors, adhesion factors, sodium / potassium ATPases and integrins (e.g., ITGAV, ITGA5, ITGB1); preferably, the migrator contains MHC molecules.

16. The migrator according to any one of claims 1 to 15, wherein the ratio of cholesterol concentration to total protein concentration of the migrator is higher than that of the cell from which it is derived, and / or The ratio of sphingomyelin concentration to total protein concentration of the migrator is higher than that of the cell from which it originates, and / or The cholesterol:phosphatidylglycerol ratio of the migrasome is higher than that of the cells from which it originates.

17. The migrating-body according to any one of claims 1-16, which is capable of inducing and / or regulating an immune response.

18. The migrator according to claim 17, wherein the immune response is selected from the group consisting of inducing activation of immune cells, production and / or secretion of cytokines, antibodies and / or other active molecules, increasing the killing function of immune cells, inducing immune memory, and increasing immune cell infiltration of tumors.

19. A vaccine composition comprising the migrator according to any one of claims 1-18.

20. The vaccine composition according to claim 19, comprising an immune adjuvant.

21. The vaccine composition according to claim 19 or 20, wherein the adjuvant is polyinosinic acid cytosine nucleotide (Poly I:C).

22. A pharmaceutical composition comprising the migrator according to any one of claims 1-18 or the vaccine composition according to any one of claims 19-21.

23. The pharmaceutical composition according to claim 22, comprising an additional therapeutic agent.

24. The pharmaceutical composition according to claim 23, wherein the other therapeutic agent is an immunomodulator.

25. The pharmaceutical composition according to claim 24, wherein the immunomodulator is selected from antibodies or antigen binding proteins thereof, binding fragments, receptors, ligands and / or compounds or any combination thereof.

26. Use of the migrator according to any one of claims 1 to 18 or the vaccine composition according to any one of claims 19 to 21 in the preparation of a medicament for preventing and / or treating a disease in a subject.

27. The use according to claim 26, wherein the disease is a tumor.

28. The use according to claim 27, wherein the tumor is a solid tumor or a hematological tumor.

29. The use according to any one of claims 26 to 28, wherein the medicament comprises an additional therapeutic agent.

30. The use according to claim 29, wherein the other therapeutic agent is an immunomodulator.

31. The use according to claim 30, wherein the immunomodulator is selected from antibodies or antigen binding proteins, binding fragments, receptors, ligands and / or compounds or any combination thereof.

32. The use according to any one of claims 26-31, wherein the migrasomes are autologous to the subject, such as generated from tumor cells isolated from a sample from the subject.

Citation Information

Cited By

  • Method for screening tumor antigen through migration body and application thereof

    CN122187938A